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A statement of the problem: Postoperative delirium is associated with poor functional 
recovery, institutionalization and high cost of medical expenditure. The objectives of the 
study were to i) identify risk factors of postoperative delirium by performing a systematic 
review; ii) develop a clinical prediction model of postoperative delirium; iii) determine 
whether cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) are 
associated with postoperative delirium. All of the objectives were explored in hip fracture 
population.  
Methods: Systematic review was conducted using prospective observational studies with 
estimation of association between preoperative risk factors and incident postoperative 
delirium in multivariable models. Risk factors identified as significant predictor of 
postoperative delirium in a hip fracture dataset of 429 individuals with acute hip fracture 
were combined with the risk factors identified from the systematic review. A clinical 
prediction model was developed and internally and externally validated. CSF was 
collected from individuals with hip fracture enrolled in a clinical trial and analyzed for 
biomarkers of Alzheimer’s disease (AD).  
Results: Search yielded 6,380 titles and abstracts from electronic databases and 72 titles 
from hand searches, and 10 studies met inclusion criteria. Cognitive impairment most 
consistently remained statistically significant after adjusting for other risk factors in 
multivariable models, followed by BMI/albumin and multiple co-morbidities.  The 
independent variables for predicting postoperative delirium in the prediction model were 
age, gender, dementia, Parkinson’s disease, American Society of Anesthesiologists 
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(ASA) Physical Status Classification, and albumin level. Our postoperative delirium 
RPM had discrimination (receiver operating characteristic ROC curve) of 0.72 with 
external validation ROC of 0.62. There was no association of CSF AD biomarkers with 
postoperative delirium.  
Conclusions: Cognitive impairment was identified as one of the strongest risk factors for 
postoperative delirium in hip fracture population. Risk stratification may be performed 
using the risk predication model (RPM) developed in hip fracture population, but the 
discrimination ability of the RPM in external validation was less than optimal. Although 
cognitive impairment was strongly associated with postoperative delirium, CSF AD 
biomarkers were not associated with postoperative delirium in a small group of hip 










Dissertation readers:  
 
Academic Advisor: Marie Diener-West PhD 
Thesis Research Mentor: Constantine Lyketsos MD MHS 
Oscar Bienvenu MD  




When I first embarked on my doctoral journey, I was at a crossroad in my career. 
I had the desire to become an independent clinician researcher, but felt that I lacked the 
necessary skill sets to move my research forward.  
I was given an opportunity to enroll in the Graduate Training Program in Clinical 
Investigation (GTPCI) with support from the Johns Hopkins Clinical Scholars Program 
(KL2), which has changed my life as a geriatrician and a researcher. The program has 
taught me the fundamentals of research, and opened my eyes to different ways of 
understanding and approaching a research question. Although the first few years of class 
work were difficult, I still recall the gratitude that I felt in being given this opportunity to 
learn from so many outstanding professors. I would like to thank Dr. Franklin Adkinson, 
Dr. Edgar Miller and Dr. Charles Flexner from the Graduate Training Program in Clinical 
Investigation (GTPCI) for giving me this opportunity, and also to thank Mr. Gregory 
Thornton of the KL2 program and Ms. Cristina DeNardo of the GTPCI who helped me 
navigate through the process. 
There are many mentors, colleagues, friends and family members who have 
faithfully supported me during my doctoral training.  I would like to thank Dr. 
Constantine Lyketsos who has been my primary research mentor for many years, and 
who has spent countless hours mentoring me. He has stood by me during early difficult 
years and believed in me even when I was not certain of my own future in academia. His 
praises during times of success, and encouragements during setbacks have enabled me to 
continue my work to this day. I am also grateful to Dr. Marie Diener-West who is my 
v 
academic advisor. Even though she has many responsibilities, she stepped into become 
my advisor when my first advisor moved to another institution, and helped me once again 
when my primary mentor for one of the studies moved abroad. She has encouraged me to 
bring my dissertation to fruition, and patiently helped me with various statistical issues 
that came up in completing the dissertation. Dr. Frederick Sieber has also been 
instrumental in developing my research career in the field of delirium, and has made it 
possible for me to develop my dissertation on postoperative delirium in hip fracture 
population. 
I would also like to thank all of the past and present members of my PhD 
committee including Dr. Constantine Lyketsos, Dr. Marie Diener-West, Dr. Frederick 
Sieber, Dr. Franklin Adkinson, Dr. Peter Zandi, Dr. Charles Flexner, Dr. Joe Bienvenu, 
Dr. Jennifer Wolff, Dr. Michelle Carlson and Dr. Milo Puhan.  
I would like to thank my colleagues who helped me with each chapter of the 
dissertation including Ms. Meng Li, Dr. Tolu Fafowora, Ms. Cathy Chen, Ms. Lori 
Rosman, and Dr. Jeannie-Marie Leoutsakos.  
 I am also indebted to all of the patients who participated in the delirium research, 
as well as the current delirium research team members including Dr. Karin Neufeld, Dr. 
Paul Rosenberg, Ms. Kori Kinbom, Ms. Rachel Burns and Mr. Michael Sklar. 
 I also wish to thank the National Institute on Aging (NIA) for funding my career 
development award (K23), and my mentors for K23 including Dr. Constantine Lyketsos, 
Dr. Marie Diener-West, Dr. Frederick Sieber, Dr. Juan Troncoso, Dr. Richard O’Brien, 
Dr. Edward Marcantonio and Dr. Sharon Inouye.   
vi 
I would also like to thank my husband Don who has been supportive of my career 
during medical school, residency, post-doctoral fellowship and now another doctoral 
degree. He encouraged me when I was discouraged and patiently listened to me during 
difficult times. I would not have been able to complete this dissertation without him. I 
would also like to thank my children Sophie and C. Paul who have given us much joy and 
love in our lives. Finally, I would like to dedicate my doctoral dissertation to my parents 
who dedicated their lives to educating their children. They were always there for me in 













TABLE OF CONTENTS 
LIST OF TABLES……………………………………………………………ix 
 
LIST OF FIGURES…………………………………………………………..xi 
 
CHAPTER I.  INTRODUCTION………………………………………...1 
   
CHAPTER II.  PREOPERATIVE RISK FACTORS FOR 
POSTOPERATIVE DELIRIUM FOLLOWING HIP 




Literature Search Strategy………………………...6 
Study Selection……………………………………6 
Data Extraction and Management………………...7 
Results………………………………………………….....8 
Study Characteristics……………………………...8 
Postoperative Delirium Assessment………………8 
Optimal Time Period of Delirium Detection……...8 
Delirium Severity and Duration of Delirium……...9 
Preoperative Risk Factors of Postoperative 
Delirium…………………………………………...9 
Cognitive Impairment……………………..9 
Age and Gender………………………….11 
Institutionalization and Functional 
Impairment……………………………….11 
BMI and Albumin………………………..12 
Multiple Comorbidities, Acute Medical. 
Conditions and American Society of 
Anesthesiologists (ASA) Physical Status 
Classifications……………………………12 
Polypharmacy………………………...….13 
Vision and Hearing Impairment…….……13 
Quality of Studies………………………………..13 
Discussion………………………………………………..14 
 
CHATPER III.  RISK PREDICTION MODEL OF POSTOPERATIVE 












CHAPTER IV. CSF BIOMARKERS OF POSTOPERATIVE DELIRIUM IN 
HIP FRACTURE POPULATION……………………..…..53 
 
Methods………………………………………..…………53 
 Inclusion/Exclusion Criteria………………….….53 
  Inclusion Criteria…………………….…..53 
  Exclusion Criteria………………………..53 







Baseline Characteristics by Postoperative Delirium  
Status…………………………………….……….56 
Baseline Characteristics by Postoperative Delirium  
Status Including Subsyndromal Delirium…..........56 
Association of Preoperative Risk Factors with 
Postoperative Delirium …………...……………..57 
Association of CSF Biomarkers with Postoperative 
Delirium by Age Categories…….……………….57 
Association of CSF Biomarkers with Preoperative 















LIST OF TABLES 
 
CHAPTER II: PREOPERATIVE RISK FACTORS FOR POSTOPERATIVE 
DELIRIUM FOLLOWING HIP FRACTURE REPAIR: A SYSTEMATIC REVIEW 
 
II.1. Methods for determining cognitive impairment/dementia………………………….20 
 
II.2. Baseline characteristics of the selected studies………………………………….21-22 
 
II.3. Analysis of risk factors by significance in bivariate models……………………23-25 
II.4. Analysis of risk factors by significance in multivariable 
models…………………...............................................................................................26-27 
 
CHAPTER III. RISK PREDICTION MODEL OF POSTOPERATIVE DELIRIUM IN 
HIP FRACTURE POPULATION 
 
III. 1. Methods for determining delirium: comparison between derivation and  
validation cohorts……………………………………………………………………...…41 
III.2. Baseline data of patients with hip fracture repair by delirium status:  
demographic and preoperative characteristics…………………………………..……42-43 
 
III.3.  Baseline data of patients with hip fracture repair by delirium status:  
demographic and preoperative characteristics among the non-demented group……..44-45 
 
III.4.  Bivariate analysis of preoperative risk factors for postoperative delirium………..46 
 
III.5.  Bivariate analysis of preoperative risk factors for postoperative delirium  
in the non-demented group………………………………………………………..……..47 
 
III.6. Multivariable analysis of preoperative risk factors for postoperative 
delirium…………………………………………………………………………………..48 
 
III.7. Multivariable analysis of preoperative risk factors for postoperative delirium  
in the non-demented group……………………………………………………………....48 
 
CHAPTER IV. CSF BIOMARKERS OF POSTOPERATIVE DELIRIUM IN HIP 
FRACTURE POPULATION 
 
IV.1. Delirium diagnostic criteria………………………………………………………..61  
x 
 
IV.2. Baseline characteristics by postoperative delirium status………………………....62 
IV.3. Baseline characteristics by postoperative delirium status including subsyndromal 
delirium…………………………………………………………………………………..63 
 
IV.4. Bivariate analysis of preoperative risk factors for postoperative delirium…….…..64 
 
IV.5. Multivariable analysis of preoperative risk factors for postoperative 
delirium…………………………………………………………………………………..65 
 
IV.6. Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by delirium 
status……………………………………………………………………………………..67 
 



















LIST OF FIGURES 
 
CHAPTER II: PREOPERATIVE RISK FACTORS FOR POSTOPERATIVE 
DELIRIUM FOLLOWING HIP FRACTURE REPAIR: A SYSTEMATIC REVIEW  
II.1. Flow diagram of search strategy……………………………………………………19 
 
CHAPTER III. RISK PREDICTION MODEL OF POSTOPERATIVE DELIRIUM IN 
HIP FRACTURE POPULATION 
III.1 Receiver operating characteristic (ROC) of internal validation for prediction  
model of postoperative delirium…………………………………………………............49  
 
III.2 Calibration of prediction model for postoperative delirium in internal validation…50 
 
III.3 Receiver operating characteristic (ROC) of external validation for prediction  
model of postoperative delirium…………………………………………………………51 
 
III.4 Calibration of prediction model for postoperative delirium in external validation...52  
 
CHAPTER IV. CSF BIOMARKERS OF POSTOPERATIVE DELIRIUM IN HIP 
FRACTURE POPULATION 
IV.1 Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by delirium  
status……………………………………………………………………………………..66 
 






































CHAPTER I.  
INTRODUCTION 
As the populations in the United States (U.S.) and other countries age, the number 
of older adults with hip fractures will continue to rise. It is estimated that the annual hip 
fracture rate in the U.S. alone is close to 300,000, and is expected to exceed 6 million 
world-wide by 2050 (1, 2). Hip fracture has the highest incidence and associated costs of 
all fractures that occur among adults 65 years and older, with estimated 2.9 billion dollars 
in Medicare costs (3). It is also associated with multitude of complications including 
prolonged rehabilitation, loss of independence, and mortality (4), with a recent study 
showing a 36 % mortality at 6 months among nursing home residents (5).  
One of the major complications of hip fracture is delirium, with an incidence of 
up to 54 % in this population (6). The new diagnostic criteria for delirium in the 
Diagnostics and Statistical Manual (DSM) V include a) disturbance in attention and 
awareness that develops over a short period of time that is a change from baseline and 
fluctuates during the course of a day, ii) additional disturbance in cognition, iii) the 
disturbances  in attention and cognition are not better explained by another preexisting 
condition, and iv) the disturbance is a direct physiological consequence of another 
medical condition, substance intoxication or withdrawal, or exposure to a toxin, or is due 
to multiple etiologies (7). As the diagnostic criteria suggest, potential etiologies for 
delirium can vary, and often they are due to multiple etiologies.  
Delirium is a complication which costs upwards of 6.5 billion dollars in Medicare 
hospital expenditures (8), and is associated with poor functional recovery (9) and 
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institutionalization (10). However, delirium is a preventable condition with available 
effective hospital-based delirium prevention approaches (11, 12). Therefore, prioritizing 
and targeting patients who are at higher risk of delirium will help clinicians in identifying 
high risk patients for close monitoring and implementation of delirium preventive 
strategies including proactive geriatrics co-management at all stages of perioperative 
care. In addition, stratification of high risk patients would enable efficient design of 
future intervention studies as well as cost effective delivery of these interventions (8, 13). 
In order to identify those who are at high risk of postoperative delirium, several 
systematic reviews have examined preoperative delirium risk factors in non-cardiac 
surgery (14), or in mixed orthopedic surgeries including elective knee and hip surgeries 
(6). However, the incidence of delirium is usually higher after hip fracture surgery (5-
53.3 %) compared to elective hip surgery (3.6-28.3 %) (6). This suggests that the type of 
surgery and underlying condition may result in different magnitudes of delirium risk 
associated with a risk factor (14). Nevertheless, systematic reviews focusing on hip 
fracture are lacking, despite its frequency, costs, and clinical relevance.  In addition, 
many of the existing studies have been limited by including patients with prevalent 
delirium and focusing solely on preoperative risk factors from bivariate analysis, which 
make it difficult to identify independent risk factors for incident delirium following 
surgery.   
One of the ways to preoperatively determine the risk for postoperative delirium is 
by using risk prediction models (RPMs) which are partly built on the risk factors 
identified from systematic reviews.  RPMs allow preoperative risk stratification of 
patients undergoing surgery, so that interventions can be targeted towards high risk 
3 
population. In the current environment where medical resources are often limited, 
targeted interventions will allow optimization of resource allocation by delivering cost-
effective care in a timely manner. Recently, there has been a systematic review 
demonstrating the effectiveness of a non-pharmacological delirium prevention method 
Hospital Elder Life Program (HELP) (12) as well as a potential pharmacological delirium 
prevention treatment such as ramelteon (15) among others. As more delirium prevention 
methods are developed in the future, development and incorporation of RPMs in research 
could potentially increase the statistical power by enriching the study population as well 
as facilitating implementation of delirium prevention methods in clinical practice.  
There are many postoperative delirium RPMs that have been developed over the 
years, but they vary in terms of the study population of interest and validation procedures, 
with few studies completing internal and external validations (16). A recent systematic 
review of postoperative delirium RPM found that of the 37 RPMs that met the review 
criteria, only three were validated internally, and four were validated externally (16). 
Among the four externally validated RPMs of postoperative delirium, only one study was 
an external validation in hip fracture population (17). As this study was a validation of a 
RPM that was originally developed on non-surgical population (18), it would be 
important to examine if the RPM that is developed from a hip fracture population would 
be different in terms of risk factors and provide better estimates of postoperative 
delirium.  
In addition to identifying clinical risk factors of postoperative delirium and 
developing RPMs based on these risk factors, there has been growing interest in 
investigation of biomarkers to assess risk of postoperative delirium (19). As underlying 
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cognitive impairment due to a neurodegenerative disease is thought to be an important 
risk factor for postoperative delirium, there has been an effort to investigate biomarkers 
of a neurodegenerative disease such as Alzheimer’s disease (AD). AD is one of the most 
common causes of dementia in the U.S., and thought to be linked to delirium (20).  
The pathology of AD is characterized by deposition of amyloid plaques and 
neurofibrillary tangles (NFT) along with degeneration of synapses and neurons (21, 22). 
Amyloid plaques are composed of extracellular deposits of the amyloid-beta 42 (Aβ42) 
and 40 (Aβ40) peptides (23), and NFTs are composed of intracellular cytoplasmic 
deposits of abnormally phosphorylated tau protein (24). More recently, the knowledge 
that AD pathology  begins many years prior to the clinical manifestation of dementia (25-
27) has led to the new AD diagnostic criteria which encompasses three different stages 
including preclinical (28), mild cognitive impairment (MCI) (29) and AD dementia (30).   
The new diagnostic criteria recommend incorporation of specific CSF biomarkers 
in diagnosing underling AD process, including decreased levels of amyloid-beta 42 
(Aβ42), increased levels of tau (total tau, phosphorylated tau 181) and increased tau/Aβ42 
ratio, which appear to be sensitive to the earliest stages in AD pathology (31, 32).  They 
are widely used in research for diagnosis of AD (30), especially in the more 
heterogeneous pre-dementia stages since they confirm the brain presence of AD 
pathology (28, 29).   
The goal of the overall study is to examine potential preoperative clinical risk 
factors for delirium after hip fracture surgery by conducting systematic review, focusing 
on studies that examined incident delirium after surgery and investigated independent 
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association of risk factors with postoperative delirium in multivariable models. After the 
identification of the clinical risk factors, a RPM based on a hip fracture population will be 
developed, then internally and externally validated.  
In addition to identifying the clinical risk factors and building a RPM, we will 
also determine whether preoperative CSF levels of AD biomarkers Aβ42, tau (t-tau, p-
tau181181) and tau/Aβ42 are associated with occurrence of postoperative delirium in 





PREOPERATIVE RISK FACTORS FOR POSTOPERATIVE DELIRIUM 
FOLLOWING HIP FRACTURE REPAIR: A SYSTEMATIC REVIEW 
METHODS 
Literature Search Strategy 
We searched PubMed, EMBASE, PsycINFO, CINAHL, and Cochrane Library 
from inception of database to April 15, 2013 without any language restrictions. We also 
searched for unpublished dissertations using Proquest Dissertations and Theses, and 
WorldCatDissertations. We hand-searched 15 journals and supplemental sections of five 
journals limited to issues published in 1990 or later (6).  Complete list of hand-searched 
journals, journal supplements and search terms for electronic and hand-searches can be 
found in Appendix 1.  
Study Selection 
The title and abstract of each article were independently reviewed by two 
reviewers. Studies were included for the following criteria: i) prospective observational 
study; ii) adult patients (≥18 age) who underwent hip fracture surgery; iii) provided data 
on incident postoperative delirium by excluding individuals who had delirium before 
surgery; iv)  included data on a concurrent, non-historical group of patients who 
underwent hip fracture surgery, but did not develop postoperative delirium; v) delirium 
assessed using Diagnostic and Statistical Manual of Mental Disorders (DSM) III or IV 
edition, or DSM derived  criteria such as Confusion Assessment Method (CAM), 
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Delirium Symptom Interview, Delirium Rating Scale, or Neelon and Champagne 
(NEECHAM) Confusion Scale; vi) risk factors examined in multivariable model. 
Studies were excluded for the following criteria: i) randomized controlled trials 
(clustered and cross-over), retrospective studies (cohort and case-control), cross-sectional 
studies, or review articles; ii) Mixed study population: data on patients who underwent 
hip fracture surgery could not be separated from other patients (e.g. other 
surgical/medical patients or elective hip surgery patients); iii) data on incident delirium 
could not be separated from prevalent (present on admission) delirium; iv) did not 
examine at least one preoperative risk factor for postoperative delirium; v) no estimate of 
association between risk factors and postoperative delirium; vi) animal study; vii) foreign 
language (non-English). Studies with only bivariate results were excluded, since our goal 
was to examine studies with adequate control for confounding. Included and excluded 
studies are reported using the PRISMA systematic review protocol (33).   
Data Extraction and Management 
Reviewers divided into two groups (EO and ML, EO and TF), and double data 
extraction and double data entry were conducted. Any discrepancies were resolved 
through discussion and consensus agreement. Quality assessment was completed by two 
independent reviewers based on pre-defined criteria. Data from Lee et al. (34) 
encompassed some of the data presented by Zakriya et al. (35) and Sieber et al. (36).  The 
latter two studies were not incorporated into the data presented in Tables II.3 and II.4. 
However, they were included in data extraction for other information in this review 
(Table II.2).  A variable was categorized as significant (S) in bivariate models if it met 
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the cut-off p-value as determined in each study (Table II.3). P-value of 0.05 was chosen 
for significance in multivariable models (Table II.4).   
RESULTS 
Study Characteristics 
Initial search yielded 6,380 titles and abstracts from the electronic databases and 
72 titles from hand searches.  After duplicates were removed, 4,786 abstracts were 
reviewed for initial screening, and 162 for the next stage of review. After inclusion and 
exclusion criteria were applied, 10 full text articles, including one dissertation, were 
chosen for detailed analysis (Figure II.1). Reasons for exclusion are listed on the flow 
diagram.   
Postoperative Delirium Assessment 
The incidence of postoperative delirium ranged widely from 13 % (37) to 55.9 % 
(38), and were identified by DSM-IV or DSM derived instrument. Among studies that 
specifically stratified preoperative risk factors by baseline cognitive function, 
postoperative delirium incidence was consistently higher in those who had cognitive 
impairment compared to those who did not (Table II.2). Some studies specifically 
excluded those with diagnosis of dementia (35, 37). 
Optimal Time Period of Delirium Detection  
One of the interesting questions to ask is if more frequent postoperative delirium 
assessments contribute to higher delirium incidence, whether longer postoperative 
assessments also result in higher delirium incidence.  Although not all articles reported 
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the incidence of delirium by postoperative days, studies reported the highest incidence on 
the first and second postoperative day.  Bjoro and Goldenberg et.al reported 91.2 % and 
78.4 % of all postoperative delirium occurred between postoperative day 1 (POD1) and 3 
(POD3), respectively (39, 40). Nie et al. also reported detecting 93.75 % of the delirium 
occurrence in between POD 1 and POD4 (37). 
Delirium Severity and Duration of Delirium  
Delirium severity was assessed in only two studies: one (40) used the MDAS, and 
the other (37) used the Delirium Rating Scale–Revised-98 (DRS-R-98) (41). Four studies 
reported delirium duration, with two reporting delirium of one day duration in 39 % (40) 
to 75 % (37) of cases. One study (38) reported an overall mean of 2.9 days for delirium 
duration, and another (42) reported duration ranging from one to nine days, with overall 
mean of 3 days.   
Preoperative Risk Factors of Postoperative Delirium 
Cognitive Impairment  
Mini-Mental Status Examination (MMSE) (43) was the most widely used tool for 
cognitive evaluation. Additional approaches to quantify preoperative cognitive state were 
the short form of the Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE-SF) (44) or the Set Test (45).  One study used an unvalidated simple four item 
screen to define preoperative cognitive status (46). Methods of classifying cognitive 
impairment status varied among studies, ranging from those that relied on cognitive 
testing tools (34-38, 40, 47) to those that also used additional information such as 
Diagnostic and Statistical Manual-IV (DSM-IV) criteria (39), incorporated evaluation by 
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clinicians (34, 36, 47), or information from medical records for additional history of 
dementia diagnosis (34, 36, 46).  
In seven studies, cognitive impairment was a significant risk factor of 
postoperative delirium in the bivariate models. It remained statistically significant in six 
out of the eight studies in the multivariable models. Among those six studies, three 
studies reported cognitive impairment to have the largest effect sizes among all the risk 
factors in the multivariable models, and two studies reported it to have the second largest 
effect sizes (Table II.4).   
Several studies further stratified the patients by cognitive status, and examined 
preoperative risk factors separately. In the cognitively impaired, female gender, femoral 
neck fracture, abnormal blood pressure, heart failure on admission, meperidine use, and 
low doses of opioid analgesia (parenteral morphine sulfate equivalents of < 10 mg/day) 
were significant preoperative risk factors in one study (46), and BMI and laboratory 
WBC values in another (40). A third study showed that only time between emergency 
department (ED) and surgery was a significant preoperative risk factor (34).  
In the cognitively intact, Functional Independence Measure (FIM) score, severe 
pain at rest and low doses of opioid analgesia (parenteral morphine sulfate equivalents of 
< 10 mg/day) were significant preoperative risk factors (46), in addition to American 
Society of Anesthesiologist (ASA) Physical Status Classification (40). One study showed 
that age, male gender, Body Mass Index (BMI), and number of medical comorbidities 
were significant preoperative risk factors (34). As the risk factors examined in these 
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studies did not overlap, it was difficult to draw conclusions from aggregated data. These 
studies also did not report whether interactions were examined in the statistical models.   
Age and Gender 
Among eight studies that examined age as a risk factor, six studies showed a 
significant association with postoperative delirium in the bivariate models (Table II.3). 
However, age remained significant in only two studies after adjusting for other risk 
factors in multivariable models, and the effect sizes were small in both studies (Table 
II.4). Only two out of five studies showed a significant association between male gender 
and postoperative delirium in the bivariate models (Table II.3), and only one remained 
significant in the final multivariable models (Table II.4).    
Institutionalization and Functional Impairment 
Among studies examining institutionalization as a risk factor for postoperative 
delirium, all showed significant associations in the bivariate models (Table II.3). 
However, none remained significant in multivariable models (Table II.4). Similarly, none 
of the studies that showed significant associations between functional impairment and 
postoperative delirium in the bivariate models (Table II.3) remained significant in the 
multivariable models (Table II.4). Methods of classifying functional impairment varied 
widely among the studies, ranging from a simple categorization as needing “help from 
others before admission”(42), to using more standardized tools such as activities of daily 
living (ADL) (34, 39, 47) to Functional Independence Measure (FIM) (46).   
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BMI and Albumin 
Three studies examined body mass index (BMI) (34, 40, 47) and three studies 
examined albumin (39, 40, 47). Two that used BMI below 20kg/m2 as impaired showed 
significant association with postoperative delirium in the bivariate models (Table II.3), 
and remained significant in the multivariable models (Table II.4).  One study that 
examined albumin < 3.5 g/dL also showed significant association with postoperative 
delirium in both the bivariate and multivariable models (Tables II.3 and II.4). 
Multiple Comorbidities, Acute Medical Conditions and American Society of 
Anesthesiologists (ASA) Physical Status Classifications 
Three out of five studies that examined multiple comorbidities found them to be 
significantly associated with postoperative delirium in the bivariate models (Table II.3). 
In two of the three this association was significant in the multivariable models as well 
(Table II.4). 
Two studies examined acute medical conditions that required treatment upon 
admission including cardiovascular or pulmonary problems (42) as well as congestive 
heart failure or abnormal blood pressure (46). These were found to be significantly 
associated with postoperative delirium in the multivariable models (Table II.4).  
Three out of four studies that examined American Society of Anesthesiologist 
(ASA) Physical Status Classification system found it to be significant in the bivariate 
models (Table II.3). However, one study did not incorporate ASA Physical Status 
Classification in the multivariable model due to collinearity (34), and the other two were 
not significant in the multivariable models (Table II.4). 
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Polypharmacy  
Similar to the categorization of multiple comorbidities, different studies used 
different criteria to define polypharmacy. One used > 3 medications (39), and others used 
> 5 medications (40, 47) to define polypharmacy.  Two showed significance in the 
bivariate models (Table II.3), but only one retained significance in the multivariable 
model (Table II.4). 
Vision and Hearing Impairment 
Only one study examined vision and hearing impairment (42). Self- reported 
vision impairment was associated with delirium in both the bivariate and multivariable 
models (Tables II.3 and II.4). Hearing impairment, which also relied on patient self-
report was not associated with post-op delirium (42). 
Quality of Studies 
Selection bias: 6 out of 10 studies specifically noted that consecutive patients 
were enrolled into the studies (34, 35, 38-40, 47). However, only 2 out of 10 compared 
baseline differences between those who were included in the study and those who were 
excluded (39, 47). There were no significant differences in age (39, 47), gender (47), 
morbidity (39), or lab values (39) in these studies.    
Measurement error: there was variability in ascertainment of baseline 
characteristics. One study collected information from medical records (38). Others 
collected information from medical records and from a combination of patient, proxy 
interviews, and staff interviews (34, 37, 40, 46). The study that reported on vision and 
14 
hearing impairment relied on self-report (42). None of the studies clearly stated whether 
outcomes were assessed by raters masked to baseline exposure/risk factors.  
Although all the studies examined clinical variables in adjusted models, only two 
studies specifically stated that effect modifications were explored by examining 
interactions between variables (47) or that collinearity was checked between risk factors. 
(34). 
DISCUSSION 
This systematic review demonstrates that cognitive impairment is the most 
consistently significant preoperative risk factor for postoperative delirium after hip 
fracture surgery, followed by BMI or albumin levels and multiple comorbidities, all of 
which had at least two studies that were significant in multivariable models with effect 
sizes greater than 1.1. Although the exact underlying pathophysiology of delirium is not 
known, some of the leading hypotheses are similar to those proposed for 
neurodegenerative processes such as Alzheimer’s disease and other types of dementia. 
One is central cholinergic deficiency representing an underlying vulnerability that 
predisposes individuals to delirium (48). Another is inflammation, which may play an 
important role both as a predisposing factor in the form of CNS inflammation as well as a 
precipitating factor from systemic inflammation such as infection (49). Therefore, it 
makes sense that in a majority of studies the most consistent risk for postoperative 
delirium is pre-existing cognitive impairment, and this finding is similar to previously 
published studies (14, 50)  
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Although baseline cognitive impairment is an important risk factor for 
postoperative delirium, cognitive assessment is often not conducted prior to emergency 
hip fracture repair. One reason is the perception that there is not enough time to perform 
cognitive testing in the preoperative setting. However, many studies, including those in 
this systematic review, demonstrate the feasibility of preoperative cognitive testing in 
emergency settings. Most studies reviewed (34-40) used MMSE, but one demonstrated 
that even a four-item screening questionnaire was sensitive enough to detect cognitive 
impairment predictive of postoperative delirium (46).  Therefore, cognitive testing should 
become part of the standard of care for preoperative assessment for hip fracture surgery. 
Another important risk factor was BMI and blood albumin levels. While low BMI 
and albumin levels are thought to represent poor nutritional status, they may also be 
reflective of inflammatory states associated with chronic disease (51). In four studies that 
examined either factor, postoperative delirium was associated with low BMI in two 
studies and low albumin in one study.  As inflammation likely plays a large role in 
delirium pathogenesis (49), BMI and albumin may be indirect measures of systemic 
inflammation related to general medical conditions. In addition, individuals with low 
albumin may be susceptible to greater bioavailability of drugs highly bound to albumin, 
and therefore at greater risk of side effects including delirium (52). 
In this review, while several studies reported age to be a significant risk for 
delirium in bivariate models, this association lost significance in all but two studies.  
While loss of statistical significance in multivariable models may be due to the narrow 
age range of subjects in these studies (53), the association between age and delirium is 
likely mediated by other risk factors, such as cognitive impairment.   
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Several studies assessed preoperative physical condition as a risk factor of 
delirium by examining number of medical comorbidities, acute medical conditions, and 
the ASA Physical Status Classification. Although disease burden is an important factor in 
delirium risk assessment, the studies reviewed had different ways of defining multiple 
comorbidities as well as acute medical conditions.  It might be more informative if 
specific conditions thought to increase postoperative delirium (e.g. vascular risk factors) 
are examined separately (54).  
An interesting finding is that although five studies showed a significant 
association between institutionalization and postoperative delirium in bivariate models, in 
none was this association significant in multivariable models. We see similar results with 
functional impairment, associated with postoperative delirium in bivariate models in five 
of six studies, but not in any multivariable models. One explanation is that these variables 
may be collinear, since most residents of skilled nursing facilities have functional 
impairments. However, this also demonstrates the robustness of the association between 
cognitive impairment and postoperative delirium, as this factor remained significant in 
multivariable models even though it is likely highly correlated with the aforementioned 
variables.   
The strengths of this systematic review include the rigorous synthesis of evidence 
across studies, involving patients across hospitals.  Important methodological advances 
over prior reviews are exclusion of prevalent delirium that allowed us to elucidate 
preoperative risk factors of incident delirium, and examination of studies that that had 
multivariable models enabling us to identify independent risk factors. This work will 
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allow development of prediction models to identify high risk groups who will benefit 
from preventive interventions for delirium.   
The limitations of this review include the small number of studies available, the 
different risk factors examined across each study, and the variability in measures and 
outcomes used.  Meta-analysis of the risk factors was not performed due to the 
limitations of the studies, as there were not enough significant risk factors in 
multivariable models among the selected studies. Although examination of preoperative 
clinical risk factors is important in understanding underlying risk, they do not explain all 
the variances in the outcome of postoperative delirium. As preoperative risk factors 
represent predisposing vulnerability, other factors such as intraoperative and 
postoperative risk factors which are precipitating risk factors are also important 
determinants of the outcome (55). 
In summary, cognitive impairment was one of the most important preoperative 
risk factors for delirium after hip fracture surgery, followed by BMI/albumin levels and 
multiple comorbidities. Given the strength of this association, a careful preoperative 
assessment of cognitive function would be most important in identifying those who are at 
the highest risk of postoperative delirium. Furthermore, future delirium intervention 
studies may be designed based on stratification of subjects by preoperative cognitive 
function. 
 In addition, baseline measures of BMI and blood albumin levels may be helpful 
in identifying those with underlying inflammatory status. While age is important, age 
18 
alone should not be used to risk stratify patients, and careful assessments of cognitive 
function and other medical conditions should be taken into account.   
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Committee Patient  
interview 
       
Andersson 
(2001) 
OBS b     √ 
Bjoro 
(2008) 
IQ-CODE-SF c     √ 
Goldenberg 
(2006) 
MMSE d, Set Test 
e 
√    √ 
Juliebo 
(2009) 






MMSE  √ √  √ 
Morrison 
(2003) 
4- item screening 
questionnaire f 
  √  √ 
Nie 
(2011) 
MMSE g  
 
    √ 
Santos 
(2005) 
MMSE      √ 
Sieber 
(2011) 
MMSE   √ √  √ 
Zakriya 
(2002) 
MMSE      √ 
 
a Diagnostic and Statistical Manual (DSM IV) (56); b Organic Brain Syndrome (OBS) 
scale (57); c Informant Questionnaire on Cognitive. Decline in the Elderly Short Form 
(IQ-CODE-SF) (44); d Mini-Mental Status Examination (MMSE) (43); e Set Test (45); f 
4-item screen (i. orientation – place and time, ii. circumstances of their fracture – place, 
time, and circumstances of their fracture, iii. immediate recall of the nature and purpose 
of the research study, iv. Recall of the name or position of the person administering the 
informed consent) (46); g Different cut-off scores were used to identify cognitive 
dysfunction depending on educational levels (MMSE <25 for middle school or higher, 
<21 for elementary school, and <18 for no schooling.). It was noted that 36 % of the 
patients had attended school or were illiterate. 
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Table II.2. Baseline characteristics of the selected studies 
a Age was categorized by those with no delirium or delirium in four studies. Age range 
was not reported in some of the studies. b Diagnostic and Statistical Manual (DSM)-IV; 
Organic Brain Syndrome (OBS) scale; Confusion Assessment Method (CAM); Memorial 
Delirium Assessment Scale (MDAS); Delirium Rating Scale-Revised (DRS-R-98). c The 
numbers indicate the proportion (%) of patients with delirium in the entire cohort. The 
proportion of patients with delirium among cognitively impaired patients are denoted in 
brackets [  ]. d Gender information was not available for the “emergency surgery” 
subgroup. e Median 84, Interquartile range (IQR) 78-88. f Age categorized in three groups 
with number of individuals in each category, but no mean, standard deviation (SD) or age 
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Table II. 3 Analysis of risk factors by significance in bivariate models 
Studies by Sieber et al (36) and Zakriya et al. (35) from Table 2 were not included in 
Table 2 because they are subgroup analysis from the same study cohort as the study by 
Lee et al. (34). Lee et al. was chosen for this analysis as the study includes the largest 
number of subjects from the same cohort. P-values are not stated if they were not 
reported or could not be calculated from other data available.a Functional impairment was 
defined differently in studies: “help from others before admission” (42), ADL score ≥ 2 
(39), Barthel index 19 or 20 (47), and FIM score (46). b BMI in quartiles (34), BMI ≤ 
20kg/m2 (40, 47), albumin <3.4g/dL (40), albumin (median value) (47), or albumin < 3.5 
g/dL (39).  c American Society of Anesthesiologist (ASA) Physical Status Classification. 
ASA group III, IV, or V (47), ASA ≥ 4 (34), ASA II, III, or IV (38), ASA I-II or III-V 
(40), d Acute medical conditions included “preoperative medical treatment for 
cardiovascular or pulmonary problems” (42), “CHF on admission” and “abnormal BP on 
admission” (46). e Polypharmacy was defined as “>5” (40),”≥5” (47), and “>3 
medications” (39).  f BMI (p=0.003), albumin (p=0.26). g The goal of this study was to 
develop a prediction model for the risk of postoperative delirium (POD).These variables 
were identified as predictors of POD in the bivariate model, but cut off p-value was not 
reported in the article. h BMI (p=0.003), albumin (p=0.64). i P-values for the stratified 
bivariate analysis by dementia status were published by Lee et.al. The p-values presented 
in this table were calculated by the author for the entire cohort from available data. j In 
this study, p <0.15 in the bivariate analysis was the cut-off value for incorporation into 
the multivariate model, and thus categorized as “significant.” k “abnormal BP” (p=0.12), 
“abnormal heart rhythm” (p=0.01),”substernal chest pain” (p=0.001), “CHF” (p<0.001), 
24 
“respiratory compromise” (p=0.59). l Nie et al. reported that different cut-off scores were 
used to identify cognitive dysfunction depending on educational levels (MMSE <25 for 
middle school or higher, <21 for elementary school, and <18 for no schooling.). 
However, baseline bivariate statistics are only reported with comparison of group mean 














































































































































































































































































































































































































































































































































II4. Analysis of risk factors by significance in multivariable models.  
P-values and effect sizes are not stated if they were not reported or could not be 
calculated from other data available. Hazard Ratio (HR), Odds Ratio (OR), Relative Risk 
(RR). a (BMI ≤ 20kg/m2) (40, 47) or albumin < 3.5 (39). b  Lee et al did not put ASA 
Physical Status Classification in the multivariate model even though they were significant 
in the bivariate model due to collinearity with other variables (34). c Acute medical 
conditions included “preoperative medical treatment for cardiovascular or pulmonary 
problems” (42), “CHF on admission” and “abnormal BP on admission” (46). d ASA 
Physical Status Classification or “severity of illness” was treated as a “precipitating 
factor” in this analysis and was incorporated into multivariate analysis with other 
precipitating factors. e P-values were calculated from OR with 95% CI reported in the 
article.  f Set Test (ST) cut off score <20 (p=0.06), MMSE <24 (p=0.03). g Age is noted as 
one of the independent predictors of POD in multivariate logistic regression analysis with 
OR of 5.1 (95% CI 0.9-26.8). Calculated p-value is 0.0598 or 0.06. Therefore, it was 
categorized as not significant (NS) in this systematic review. h In this study, the highest 
RR was 5.4 for parenteral morphine sulfate equivalent of < 10 mg per day.  i “abnormal 
BP” (RR 2.3; p=0.01), “abnormal heart rhythm” (RR 1.7; p=0.3),”substernal chest pain” 
(RR1.9; p=0.4), “CHF” (RR 2.9; p<0.001), j Nie et al. did not report a p-value, but 
























































































































































































































































































































































































































































































































































































































































































The derivation cohort was derived from a study which comprised of 726 
consecutive hip fracture repair patients above age 65 who were approached for consent to 
collect their peri-operative clinical data for research purpose from 1999 and 2008 at the 
Johns Hopkins Bayview Medical Center. Patients who were determined to have 
preoperative delirium by a trained research nurse based on the Confusion Assessment 
Method (CAM) (58) were ineligible for the study.  Of the remaining eligible patients, 429 
individuals with complete postoperative delirium data were included in the analysis. 
Postoperative delirium was measured by CAM on the second postoperative day (POD2). 
Confusion Assessment Method (CAM) consists of two core features 1) acute onset and 
fluctuating course 2) inattention, and two other supporting features 3) disorganized 
thinking and 4) altered level of consciousness. The diagnosis of delirium by CAM 
requires the presence of features 1 and 2 and either 3 or 4 (58). The study was approved 







The derivation cohort was also stratified by cognitive status, and a separate cohort 
of 287 individuals who did not meet the criteria for probable dementia diagnosis was 
established. This cohort will be hitherto referred as the “non-demented” group.  
Validation cohort 
The validation cohort was derived from a study which comprised of 83 
consecutive hip fracture repair patients who were enrolled in the study A Strategy to 
Reduce the Incidence of Post-operative Delirium in Elderly patients (STRIDE). This 
study was started at the Johns Hopkins Bayview Medical Center in November 2011 and 
is still on-going at this time. STRIDE is a randomized controlled trial of light versus 
heavy intraoperative sedation (anesthesia) in individuals with hip fracture. Exclusion 
criteria include preoperative delirium at the time of screening, refusal or inability to have 
spinal anesthesia, or MMSE less than 15. Delirium assessments are completed by trained 
research assistants who administers MMSE (43), CAM, Digit Span, and Delirium Rating 
Scale-Revised-98 (DRS-R-98) (41) preoperatively, and then daily from postoperative day 
(POD) 1 to POD 5 or up to the time of hospital discharge. They also interview the 
patient, family, nurse and review medical records including physician notes. Consensus 
Diagnostic Committee (CDC) consisting of two psychiatrists and one geriatrician arrive 
at a consensus diagnosis of delirium based on the data collected by the research 
assistants. For this study, a patient was classified to have postoperative delirium if he or 
she had CDC adjudicated delirium diagnosis at any time during the hospitalization. The 
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methods for determining delirium for the derivation and validation cohort are 
summarized in Table III.1. 
Preoperative risk factors for building prediction model were chosen based on 
previous data analyses involving this study population and from the literature including 
systematic reviews (16, 18, 59, 60). Preoperative Risk factors were categorized into 
demographics including age, gender, race, current smoking status, current alcohol use, 
body mass index (BMI); neurological and psychiatric including history of probable 
dementia, cerebrovascular accident (CVA)/transient ischemic attack (TIA)/carotid 
endarterectomy (CEA) diagnosis, Parkinson’s disease, depression, and psychiatric 
disorder other than depression; medical comorbidities including number of comorbidities, 
coronary artery disease (CAD), congestive heart failure (CHF), atrial fibrillation, 
hypertension (HTN), diabetes (DM), chronic renal insufficiency (CRI), peripheral 
vascular disease (PVD), chronic obstructive pulmonary disease (COPD), cancer, 
hypothyroidism, syncope, and American Society of Anesthesiologists (ASA) Physical 
Classification. Probable dementia diagnosis was assigned if either the patient had a 
MMSE score of less than 24 (43) or was given a diagnosis of dementia by a geriatrician 
during pre-operative evaluation. MMSE cut-off score was used to capture patients with 
possible underlying dementia who may not have been recognized on outpatient basis 
(59).  
Analyses 
 Preoperative factors were compared between individuals who experienced 
postoperative delirium and those who did not using t-test for continuous variables and χ2 
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test for dichotomous or categorical variables. The selected variables were examined for 
their missingness. All of the chosen variables had less than 10 % of missing values except 
two variables height and albumin level, which had missing variables of 15.9 % and 
16.1 % respectively. Since BMI (derived from height and weight) and albumin level were 
determined to be important risk factors for postoperative delirium in hip fracture 
population (60), these variables were also included in the model after two fold multiple 
imputation was performed using Imputation by Chained Equations (ICE). BMI variable 
was created after the multiple imputation of height and weight variables. We also 
conducted sensitivity analysis based on missingness of the variables BMI and albumin 
prior to multiple imputation, and the incidence of delirium was not statistically different 
between those who were missing these variables compared to those who were not.  
Variables that were identified as independent risk factors (p ≤ 0.10) of 
postoperative delirium in the bivariate analysis were chosen for backward step-wise 
multivariable selection, which is considered to be superior to forward selection (61). 
Collinearity among all of the chosen variables was examined by testing variance inflation 
factors (VIF) both in the original and the imputed dataset. In addition, further 
examination of potential collinearity among variables which may reflect 
frailty/inflammatory state including BMI, albumin level and Parkinson’s disease (62, 63) 
were performed separately in the original and imputed dataset. Following the events per 
variable (EPV) rule with 10 events allowed per variable, (64, 65) it was determined that 
the model allowed up to 14 variables (147/429 subjects with postoperative delirium).  
If a risk factor was available in different types of variable, an effort was made to 
choose continuous variable over dichotomous or categorical variable. Some variables that 
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were available as both continuous and categorical variables were separately tested in 
multivariable models to determine which had the best fit in the model. Age was tested as 
a continuous or a categorical (decades) variable, and the American Society of 
Anesthesiologists (ASA) Physical Status Classification System was tested as a 
categorical (1 to 4) or a dichotomous (ASA < 4 or ASA ≥ 4) variable (66). Number of 
comorbidities were tested as a continuous or a dichotomous variable based on the median 
number of comorbidities (5) in the cohort (≤ 5 or >5).  BMI was tested as a continuous or 
a categorical variable (underweight BMI < 18.5, normal 18.5 ≤ BMI < 25, overweight 25 
≤ BMI <30, obese BMI ≥ 30 in/ft2).  Albumin was also tested as a continuous variable, 
two dichotomous variables with different cut off values (albumin < 3.5 or ≥ 3.5 mg/dL) 
or (albumin < 3.4 or ≥ 5.0 mg/dL). The former cut off value was based on the literature 
(39) and the latter based on the study institution’s reference range.  Other laboratory 
values including hemoglobin, blood urea nitrogen (BUN)/creatinine ratio, and white 
blood cell (WBC) counts were dichotomized by the reference range set by the study 
institution. As the interaction between age and gender was found to be one of the 
important preoperative risk factors of postoperative delirium in this study population (in 
press, Oh, et al., the Journal of the American Geriatrics Society), age-gender interaction 
term was also tested in the model.   
Receiver operating characteristic (ROC) was used as the primary statistic of 
model performance, and internal validation was performed with bootstrap resampling 
procedure (67). Averages of bootstrap performance was derived from 1,000 repetitions, 
and estimated performance was derived by correcting for optimism (68).  In order to 
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determine whether the model is a good fit for the data, Hosmer-Lemeshow goodness-of-
fit test was performed. (69) 
External validation was performed on hip fracture population at the same 
institution (Johns Hopkins Bayview Medical Center) from a different time period 
(temporal validation).  Although there were five subjects with dementia diagnosis, 
MMSE < 24 was used as a surrogate for “probable dementia” diagnosis in order to be 
more congruent with the derivation cohort. All statistical analyses were performed using 
STATA (College Station, TX: StataCorp LP).  
RESULTS 
The overall incidence of postoperative delirium in the derivation population was 
34 % (147/429).  At baseline, mean age of the study population was 81 (SD 6.9). They 
were more likely to be female and predominantly white. Roughly a third (33 %) of the 
patients met the predefined criteria for probable dementia.  Among the medical co-
morbidities, hypertension (HTN) was the most common comorbidity, followed by 
coronary artery disease (CAD) and diabetes. Most patients were in the ASA Physical 
Classification 3, which is designated for patients with severe systematic disease (70). In 
terms of laboratory values, none of the preoperative risk factors examined including 
anemia, azotemia, leukocytosis or low albumin levels differed by postoperative delirium 
status (Table III.2). The baseline characteristics were similar in the non-demented 
subgroup, with exception of history of PD, which was no longer statistically significant at 
baseline (Table III.3) 
In bivariate analysis of the derivation set, individuals who were older or male 
gender had higher risk of delirium. Probable dementia or Parkinson’s disease (PD) was 
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also associated with higher risk of delirium, and there was a trend towards significance 
with history of CVA/TIA/CEA. Among co-morbidities, history of CHF or atrial 
fibrillation was associated with higher risk of delirium as were number of comorbidities 
and higher level of the ASA Physical Classifications System (Table III.4). In the non-
demented group, the bivariate associations remained similar except for BMI, history of 
psychiatric disorder other than depression, and history of peripheral vascular disease 
(PVD) which were significantly associated in the non-demented group, and PD which 
was not significant.  
There were total of 147 postoperative delirium episodes, which allowed selection 
of up to 14-15 variables for our prediction model (64, 65). There were 10 variables that 
were chosen for modeling building, including 8 variables that were chosen based on 
having the cut-off of p≤ 0.10 in bivariate analysis (age, gender, probable dementia, 
Parkinson’s disease, CHF, atrial fibrillation, number of comorbidities, and ASA) (Table 
III.4) and 2 variables that were chosen from the systematic review (BMI and albumin) 
(60). Using cut-off of p ≤ 0.1, step-wise regression was performed by backward 
elimination. The following 6 variables remained in the model including age (continuous), 
gender (dichotomous), probable dementia (dichotomous), Parkinson’s disease 
(dichotomous), ASA (categorical) and albumin (continuous) (Table III.6). CHF, atrial 
fibrillation, number of comorbidities, and BMI were eliminated.  
In the non-demented subgroup, there were 72 postoperative delirium episodes. 
There were 10 variables that were chosen for model building, including 9 variables that 
were chosen based on having the cut-off of p ≤ 0.1 in bivariate analysis (age, gender, 
BMI, history of psychiatric disorder other than depression, CHF, atrial fibrillation, PVD, 
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number of comorbidities, and ASA) (Table III.5) and 1 variable that was chosen from the 
systematic review (albumin).Using cut-off of p ≤ 0.1, step-wise regression was 
performed by backward elimination. The following 5 variables remained in the model 
including age (continuous), gender (dichotomous), history of psychiatric disorder other 
than depression (dichotomous), PVD (dichotomous), and ASA (categorical) (Table III.7). 
CHF, atrial fibrillation, number of comorbidities, BMI and albumin were eliminated. 
Internal validation using bootstrap technique with 1000 repetitions was performed 
with the model including only independent predictors. The receiver operating 
characteristic (ROC) was 0.73 (Figure III.1) optimism was 0.01, with resulting optimism 
corrected ROC of 0.72. Hosmer-Lemeshow goodness-of-fit test showed that the 
probability that a χ2 statistic exceeds 12.49 was p = 0.13 (Figure III.2), therefore this test 
did not provide evidence to reject the model. External validation with the validation 
cohort resulted in ROC of 0.63 (Figure III.3). Hosmer-Lemeshow goodness-of-fit test 
showed that the probability that a χ2 statistic exceeds 14.83 was p = 0.06 (Figure III.4).  
When the interaction variable of age and gender was incorporated into the 
analysis, it resulted in a model with 9 variables including age, gender, age*gender 
(interaction), probable dementia, Parkinson’s disease, number of comorbidities, ASA, 
and albumin. Although incorporation of an interaction variable of age and gender resulted 
in a prediction model with superior discrimination (ROC 0.75), the external validation 
was inferior (ROC 0.57).  
In the non-demented subgroup, the internal validation using bootstrap technique 
with 1000 repetitions resulted in ROC of 0.70 and optimism of 0.03, with resulting 
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optimism corrected ROC of 0.67. External validation was not completed as history of 
psychiatric disorder other than depression was not collected as part of the validation 
cohort.  
DISCUSSION 
In this study, we developed a new preoperative risk prediction model (RPM) of 
postoperative delirium in hip fracture population. We identified 6 preoperative risk 
factors including age, gender, dementia, Parkinson’s disease, ASA Physical Status 
Classification, and albumin level, and developed a RPM which performed moderately 
well in internal validation (ROC = 0.72). However, the model performed less than 
optimally in the external validation.  
The innovation of our model is that this RPM was developed based on risk factors 
identified from a hip fracture population, as compared to a previous model which was 
developed with risk factors identified from a general medical population and applied to a 
hip fracture population (17).  The strengths of this RPM include selection of risk factors 
based on prior studies in this population including a systematic review which specifically 
examined preoperative risk factors of postoperative delirium in hip fracture population 
(60), which is considered to be of great importance (71). We also applied multiple 
imputation to minimize missing data in variables that were identified as important in the 
systematic review. Finally, bootstrapping technique for internal validation was used, 
which provides stable estimates with low bias compared to split-sample analyses or 
cross-validation methods (68).   
One of the reasons for less than optimal external validation result of our 
prediction model may be due to the issues of methodological transportability. Differences 
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in the methods used to define variables and collect data can result in problems with 
methodological transportability in external validation (72).  One of the most important 
differences between the derivation cohort and validation cohort in our study is 
ascertainment of postoperative delirium as noted in Table III.1. In the derivation cohort, 
postoperative delirium assessments were done on postoperative day 2, whereas in the 
validation cohort, they were completed from postoperative day 1 to day 5 or up to the day 
of discharge. In addition, delirium outcome in the derivation cohort was based on the 
CAM, but in the validation cohort, delirium outcome was based on the adjudication from 
the Consensus Diagnosis Committee (CDC). The CDC considered more comprehensive 
information including the CAM, DRS-R-98, MMSE, history from informants and 
medical records. Another difference is ascertainment of probable dementia. In the 
derivation cohort, dementia variable was a combined variable of either having MMSE 
less than 24 or having preoperative diagnosis of dementia by a physician. In the 
validation cohort, dementia variable was based on MMSE less than 24 only, as baseline 
data of dementia diagnosis is not complete at this time. Finally, the external validation 
was performed in a small subset of a cohort, due to the nature of the on-going study.  
Another reason for the poor external validation results may be that even though 
the underlying cognitive impairment/dementia is an important risk factor, the validation 
cohort consists of relatively cognitively intact cohort. This may be due to the fact that one 
of the exclusion criteria is MMSE <15, whereas there was no MMSE exclusion criteria in 
the derivation cohort. Although an attempt was made to develop a separate RPM model 
based on “non-demented” individuals from the derivation cohort, it was less than optimal 
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as it was built on a smaller group of individuals and due to some of the significant 
variables missing in the validation cohort.  
There are also other variables such as preoperative functional status and frailty 
which are thought to be important preoperative risk factors for postoperative delirium, 
but were not incorporated in the current model because these variables were not 
consistently collected in the data set of the derivation cohort. BMI was found to be 
significant in two of the studies selected for a systematic review of risk factors for 
postoperative delirium in hip fracture population (60). However, it did not come up as a 
significant variable in step-wise regression performed by backward elimination even 
though different models were tested with BMI both as a continuous and as a categorical 
variable. In addition, when different bootstrap models with and without BMI were 
compared, the more parsimonious model without BMI performed slightly better in terms 
of discrimination.  
One of the most important findings that we can learn from this study is that 
preoperative risk factors alone cannot explain all the risks for postoperative delirium in 
hip fracture population. There are also intraoperative and postoperative factors that are 
important risk factors for development of postoperative delirium that are difficult to know 
prior to surgery. However, preoperative RPM may be useful in stratifying patients for 
interventions to prevent delirium by enriching the target population. In addition, there 
may be biomarkers that may be developed in the future that can strengthen the 
discrimination power of the preoperative RPM for postoperative delirium. Future 
directions include temporal validation on full dataset once the STRIDE population of 200 
subjects becomes available. In addition, a full external validation on a hip fracture 
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√ √ √ POD1-5 or 
discharge 
      
 
a Confusion Assessment Method (CAM) (58); b Postoperative day (POD);  c Delirium 



















Table III.2.  Baseline data of patients with hip fracture repair by delirium status:  
demographic and preoperative characteristics 
a Body Mass Index (BMI) (N = 356, 17 % missing value). Percentages were calculated 
based on total N = 356, N = 239 in “No delirium” group and N = 117 in “Delirium” 
group; b Clinical history of previous stroke or transient ischemic attacks or carotid 
endarterectomy; c Psychiatric disorders other than depression; d  Coronary Artery Disease 
- clinical history of previous myocardial infarction or angina or coronary 
revascularization (angioplasty, CABG); e  Congestive Heart Failure - documentation of 
prior hospital admission with congestive heart failure or ejection fraction < 40 %; ; f 
Peripheral Vascular Disease – history or surgical procedure performed for PVD, 
claudication, inter-arm asymmetry in blood pressure;  g Chronic Renal Insufficiency – 
serum creatinine > 1.5 mg/dl in males or > 1.3 mg/dl in females ; h Number of 
comorbidities;  i ASA - American Society of Anesthesiologist Physical Status 
Classification System (1. A normal healthy patient; 2. A patient with mild systemic 
disease; 3. A patient with severe systemic disease; 4. A patient with severe systemic 
disease that is a constant threat to life (70) (N = 418, 2.6 % missing value). Percentages 
were calculated based on total N = 418, N = 275 in “No delirium” group and N = 143 in 
“Delirium” group; j Anemia - Male hematocrit <41, Female hematocrit <36. k Azotemia - 
BUN/creatinine ratio >20; l Leukocytosis ->11,000 WBC in the initial CBC; m Albumin 
as a continuous variable – mean 3.98 mg/dL (SD 0.52). There was no statistically 
significant difference between those without delirium compared to those with delirium 




Table III.2.  Baseline data of patients with hip fracture repair by delirium status:  





(N = 429) 
No 
Delirium 
(N = 282) 
 
Delirium 
(N = 147) 
 
P-value 
Demographics & BMI     
   Age-years,  mean ± (SD) 81   (6.9) 80   (6.9) 82   (6.8)   0.002  
   Gender, male (%) 115 (26.8) 63   (22.3) 52   (35.4)   0.004 
   Race, non-white, n (%) 19   (4.4) 12   (4.3) 7     (7.4)   0.89 
   Current smoking, n (%) 67   (15.6) 46   (16.3) 21   (14.3)   0.53 
   Current alcohol use, n (%) 51   (11.9) 34   (12.1) 17   (11.6)   0.83 
   Body mass index a     
      <18.5 (underweight), n (%) 48   (13.5) 30   (12.6) 18   (15.4)   0.61 
        18.5-24.9 (normal), n (%) 167 (46.9) 109  (45.6) 58   (49.6)  
        25.0-29.9 (overweight), n (%) 103  (28.9) 72    (30.1) 31   (26.5)  
      ≥30.0 (obese), n (%) 38    (10.7) 28    (11.7) 10    (8.5)  
     
Neurological & Psychiatric     
   Dementia, n (%)  142 (33.1) 67   (23.8) 75   (51) <0.001   
   CVA/TIA/CEA b, n (%) 83   (19.3) 47   (16.7) 36   (24.5)   0.05 
   Depression, n (%)  69   (16.1) 43   (15.2) 26   (17.7)   0.51 
   Psychiatric disorder c, n (%) 41   (9.6) 23   (8.2) 18   (12.2)   0.18 
   Parkinson’s disease, n (%) 13   (3.0) 5     (1.8) 8     (5.4)   0.04 
     
Medical      
   Hypertension, n (%) 312 (72.0) 206 (73.05) 106 (72.11)   0.79 
   CAD d, n (%) 124 (28.9) 82   (29.08) 42   (28.57)   0.90 
   Diabetes, n (%) 101 (23.5) 72   (25.5) 29   (19.7)   0.18 
   COPD, n (%) 92   (21.4) 62   (22.0) 30   (20.4)   0.69 
   CHF e, n (%) 85   (19.8) 48   (17.0) 37   (25.2)   0.05 
   Atrial fibrillation, n (%) 82   (19.1) 46   (16.3) 36   (24.5)   0.04 
   Cancer, n (%) 65   (15.2) 43   (52.4) 22   (15.0)   0.93 
   Hypothyroidism, n (%) 63   (14.7) 43   (15.2) 20   (13.6)   0.64 
   PVD f, n (%) 52   (12.1) 30   (10.6) 22   (15.0)   0.20 
   CRI g, n (%) 48   (11.2) 31   (11.0) 17   (11.6)   0.88 
   Syncope, n (%) 22   (5.1) 11   (3.9) 11   (7.5)   0.11 
   #Comorbidities h, mean ± (SD)  4.8  (2.4) 4.5   (2.3) 5.5  (2.6) <0.001   
   ASA 2 i, n (%) 72   (17.2)  63   (22.9) 9     (6.3) <0.001   
   ASA 3 290 (69.4) 184 (66.9) 106 (74.1)  
   ASA 4 56   (13.4) 28   (10.2) 28   (19.6)  
     
Laboratory      
   Anemia j, n (%) 233  (54.3) 154 (54.6) 79 (53.7)   0.86 
   Azotemia k, n (%) 220  (51.3) 143 (50.7) 77 (52.4)   0.72 
   Leukocytosis l, n (%)   139  (32.4) 93 (33.0) 46 (31.3)   0.54 
   Low albumin m, n (%) 47    (11.0) 36 (12.8) 11 (7.5)   0.15 
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Table III.3.  Baseline data of patients with hip fracture repair by delirium status:  
demographic and preoperative characteristics among the non-demented group 
a Body Mass Index (BMI) (N = 252, 12 % missing value). Percentages were calculated 

















Table III.3.  Baseline data of patients with hip fracture repair by delirium status:  




(N = 287) 
No 
Delirium 
(N = 215) 
Delirium 
(N = 72) 
P-value 
Demographics & BMI     
   Age-years,  mean ± (SD) 80   (7.0) 79   (6.9) 81   (7.0)   0.02  
   Gender, male (%) 78   (27.8) 50   (23.3) 28   (38.9)   0.01 
   Race, non-white, n (%) 10   (3.5) 7     (3.3) 3     (2.0)   0.72 
   Current smoking, n (%) 46   (16.0) 38   (17.7) 8     (11.1)   0.18 
   Current alcohol use, n (%) 35   (12.3) 29   (13.6) 6     (8.5)   0.25 
   Body mass index a     
      <18.5 (underweight), n (%) 31   (12.3) 21   (11.0) 10   (16.1)   0.19 
        18.5-24.9 (normal), n (%) 113 (44.8) 82   (43.2) 31   (50.0)  
        25.0-29.9 (overweight), n (%) 79   (31.4) 61   (32.1) 18   (29.0)  
      ≥30.0 (obese), n (%) 29   (11.5) 26   (13.7) 3     (4.8)  
     
Neurological & Psychiatric     
   CVA/TIA/CEA, n (%) 46   (16.0) 31   (14.4) 15   (20.8)   0.20 
   Depression, n (%)  40   (13.9) 29   (13.5) 11   (15.3)   0.68 
   Psychiatric disorder, n (%) 30   (10.5) 18   (8.4) 12   (16.7)   0.05 
   Parkinson’s disease, n (%) 8     (2.8) 4     (1.9) 4     (5.6)   0.10 
Medical      
   Hypertension, n (%) 208 (72.5) 156 (72.6) 52   (72.2)   0.91 
   CAD, n (%) 86   (29.0) 67   (31.2) 19   (26.4)   0.43 
   Diabetes, n (%) 67   (23.3) 53   (24.7) 14   (19.4)   0.36 
   COPD, n (%) 61   (21.3) 46   (21.4) 15   (20.8)   0.91 
   CHF, n (%) 57   (19.9) 36   (16.7) 21   (29.2)   0.02 
   Atrial fibrillation, n (%) 51   (17.8) 31   (14.4) 20   (27.8)   0.01 
   Cancer, n (%) 40   (13.9) 33   (15.4) 7     (9.7)   0.23 
   Hypothyroidism, n (%) 36   (12.5) 29   (13.5) 7     (9.7)   0.40 
   PVD, n (%) 34   (11.8) 30   (14.0) 22   (30.6)   0.01 
   CRI, n (%) 26   (9.1) 21   (9.8) 5     (6.9)   0.46 
   Syncope, n (%) 14   (4.9) 9     (4.2) 5     (6.9)   0.35 
   #Comorbidities, mean ± (SD)  4.5  (2.4) 4.3  (2.2) 5.1  (2.7)   0.01   
   ASA 2, n (%) 60   (20.9)  54   (25.1) 6     (8.3)   0.003 
   ASA 3 195 (67.9) 142 (66.0) 53   (73.6)  
   ASA 4 32   (11.1) 19   (8.8) 13   (18.1)  
     
Laboratory      
   Anemia, n (%) 147  (51.2) 111 (51.6) 36 (50.0)   0.81 
   Azotemia, n (%) 137  (47.7) 104 (48.4) 33 (45.8)   0.73 
   Leukocytosis, n (%)   88    (30.1) 70   (32.6) 18 (25.0)   0.27 









   
Risk Factors Odds Ratio  
(95% CI) 
p-value 
Demographics & BMI   
   Age-years  1.05 (1.02, 1.08)   0.002 
   Gender (male) 1.90 (1.23, 2.95)   0.004   
   Race 1.15 (0.51, 2.63)   0.74 
   Current Smoking  0.84 (0.48, 1.47)   0.53 
   Current Alcohol use 0.93 (0.50, 1.74)   0.83 




   Dementia  3.34 (2.19, 5.11) <0.001 
   CVA/TIA/CEA 1.61 (0.99, 2.63)   0.06 
   Depression diagnosis 1.20 (0.71, 2.05)   0.51 
   Psychiatric disorder 1.56 (0.81, 2.99)   0.18 
   Parkinson’s disease 3.18 (1.02, 9.89)   0.05 
   
Medical   
   Hypertension 0.94 (0.60, 1.47)   0.79 
   CAD  0.97 (0.62, 1.51)   0.90 
   Diabetes 0.72 (0.44, 1.17)   0.19 
   COPD 0.91 (0.55, 1.48)   0.69 
   CHF  1.63 (1.01, 2.65)   0.05 
   Atrial fibrillation 1.66 (1.01, 2.71)   0.04 
   Cancer 0.97 (0.56, 1.70)   0.93 
   Hypothyroidism 0.87 (0.49, 1.55)   0.64 
   PVD 1.47 (0.82, 2.66)   0.20 
   CRI 1.05 (0.56, 1.96)   0.88 
   Syncope 1.98 (0.84, 4.70)   0.12 
   # Comorbidities 1.17 (1.08, 1.28) <0.001 
   ASA 2.47 (1.66, 3.69) <0.001 
   
Laboratory    
   Anemia 0.97 (0.65, 1.44)   0.86 
   Azotemia 1.08 (0.72, 1.61)   0.72 
   Leukocytosis 0.87 (0.56, 1.35)   0.54 





Table III.5.  Bivariate analysis of preoperative risk factors for postoperative 




   
Risk Factors Odds Ratio  
(95% CI) 
p-value 
Demographics & BMI   
   Age-years  1.05 (1.00, 1.09)   0.03 
   Gender 2.10 (1.19, 3.71)   0.01   
   Race 1.36 (0.48, 3.90)   0.57 
   Current Smoking  0.58 (0.25, 1.30)   0.18 
   Current Alcohol use 0.59 (0.23, 1.47)   0.26 




   CVA/TIA/CEA 1.56 (0.79, 3.10)   0.20 
   Depression diagnosis 1.17 (0.55, 2.48)   0.68 
   Psychiatric disorder 2.17 (0.99, 4.75)   0.05a 
   Parkinson’s disease 3.10 (0.76, 12.74)   0.12 
Medical   
   Hypertension 0.97 (0.53, 1.76)   0.91 
   CAD  0.79 (0.43, 1.43)   0.43 
   Diabetes 0.73 (0.38, 1.42)   0.36 
   COPD 0.96 (0.50, 1.85)   0.91 
   CHF  2.05 (1.10, 3.81)   0.02 
   Atrial fibrillation 2.28 (1.20, 4.33)   0.01 
   Cancer 0.59 (0.25, 1.40)   0.23 
   Hypothyroidism 0.69 (0.29, 1.64)   0.40 
   PVD 2.70 (1.29, 5.65)   0.008 
   CRI 0.69 (0.25, 1.89)   0.47 
   Syncope 1.70 (0.55, 5.25)   0.36 
   # Comorbidities 1.15 (1.03, 1.29)   0.01 
   ASA 2.41 (1.44, 4.03)   0.001 
   
Laboratory    
   Anemia 0.94 (0.55, 1.60)   0.81 
   Azotemia 0.91 (0.53, 1.56)   0.73 
   Leukocytosis 0.71 (0.38, 1.32)   0.27 
   Albumin 1.24 (0.48, 3.21)       0.65 





Table III.6. Multivariable analysis of preoperative risk factors for postoperative 
delirium 
Risk Factors Odds Ratio 
(95% CI) 
p-value 
Age 1.04 (1.00, 1.07)   0.03 
Gender (male) 2.28 (1.40, 3.73)   0.001 
Dementia 2.91 (1.85, 4.57) <0.001 
Parkinson’s disease 4.34 (1.16, 16.26)   0.03 
ASA 2.02 (1.32, 3.08)   0.001 
Albumin (mg/dL) 1.63 (1.03, 2.59)   0.04 
   
 
*Logistic regression based on multiply imputed (x1) dataset 
 
Table III.7. Multivariable analysis of preoperative risk factors for postoperative 
delirium in the non-demented group 
Risk Factors Odds Ratio 
(95% CI) 
p-value 
Age 1.05 (1.01, 1.10)   0.02 
Gender (male) 2.31 (1.24, 4.30)   0.01 
Psychiatric disordera 2.46 (1.05, 5.75)   0.04 
PVDb 2.37 (1.08, 5.23)   0.03 
ASA 1.90 (1.09, 3.29)   0.02 
   
 
*Logistic regression based on multiply imputed (x1) dataset 










Figure III.1 Receiver operating characteristic (ROC) of internal validation for 
prediction model of postoperative delirium.  
 
Internal validation using bootstrap technique with 1000 repetition and adjusted for 
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Figure III.2 Calibration of prediction model for postoperative delirium in internal 
validation.  
 
Hosmer-Lemeshow goodness-of-fit test showed that the probability that a χ2 statistic 
exceeds 12.49 was p = 0.13 (Figure 2), therefore this test did not provide evidence to 
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Figure III.3 Receiver operating characteristic (ROC) of external validation for 
prediction model of postoperative delirium. 
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Figure III.4 Calibration of prediction model for postoperative delirium in external 
validation.  
 
Hosmer-Lemeshow goodness-of-fit test showed that the probability that a χ2 statistic 
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CSF BIOMARKERS OF POSTOPERATIVE DELIRIUM IN HIP FRACTURE 
POPULATION 
METHODS 
The study is comprised of 83 consecutive hip fracture repair patients who were 
enrolled in the study A Strategy to Reduce the Incidence of Post-operative Delirium in 
Elderly patients (STRIDE). This study was started at the Johns Hopkins Bayview 
Medical Center in November 2011 and is still on-going at this time. STRIDE is a 
randomized controlled trial of light versus heavy intraoperative sedation (anesthesia) in 
individuals with hip fracture.  
Inclusion/Exclusion Criteria 
Inclusion Criteria 
(a) Patient is able to read, write, speak and understand English, and Mini-Mental 
State Examination (MMSE) (43) score ≥ 15 (max=30).  
Exclusion Criteria 
(a) Patient does not meet guidelines to receive spinal anesthesia, (b) patient 
refusal to give informed consent, (c) patient is younger than 65 years of age at admission, 
(d) patient is unable to read/write/speak/understand English, (e) MMSE < 15, (f) patient 
has preoperative delirium, (g) patient is intubated, (h) patient has severe chronic 
obstructive pulmonary disease (COPD) based on the Gold Initiative for Chronic 
Obstructive Lung Disease (GOLD) executive summary statement, as follows: 1. post-
bronchodilator FEV1 < 30 % predicted or FEV1 < 50 % predicted + chronic respiratory 
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failure, (chronic respiratory failure is defined as PaO2 < 60 mm Hg with or without 
PaCO2 > 50mm Hg while breathing air at sea level), 2. post-bronchodilator FEV1/FVC < 
0.70, (k) patient has severe congestive heart failure (CHF) defined as New York Heart 
Association Functional Classification, Level IV.  
Cognitive Assessments 
Patients were evaluated for preoperative cognitive function by Mini Mental State 
Examination (MMSE) (43), Clinical Dementia Rating (CDR) (73), and history of 
dementia on the Charlson Comorbidity Index questionnaire (74).  Consensus Diagnostic 
Committee (CDC) consisting of two psychiatrists and one geriatrician arrived at a 
consensus CDR score based on the information gathered from the informant.  
Delirium Assessments 
Delirium assessments were completed by trained research assistants who 
administered MMSE, Confusion Assessment Method (CAM) (58), Digit Span, and 
Delirium Rating Scale-Revised-98 (DRS-R-98) (41) preoperatively, and then daily from 
postoperative day (POD) 1 to POD 5 or up to the time of hospital discharge. They also 
interviewed the patient, family, nurse and reviewed medical records including physician 
notes.  
Delirium Diagnosis 
Consensus Diagnostic Committee (CDC) arrived at a consensus diagnosis of 
delirium based on the data collected by the research assistants. For this study, a patient 
was classified to have postoperative delirium if he or she had CDC adjudicated delirium 
diagnosis at any time during the postoperative period (Table IV.1). The diagnosis of 
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subsyndromal delirium was given if the clinical scenario did not meet all three criteria for 
delirium, but one or two of the criteria were met.  
Analyses 
Laboratory Analyses 
CSF samples were collected during routine spinal anesthesia, aliquoted and stored 
at – 80 F. Previously unthawed CSF samples were analyzed for full-length amyloid-beta 
42 (Aβ42), total tau and tau phosphorylated on threonine 181 (p-tau181) using the XMAP 
based Innogenetics AlzBio3 kit run on the Bio-plex 200 (Luminex) system (75). Each 
sample was run in triplicate, and analyzed on the same plate. Based on previous 
experiments, intra-assay coefficients of variation for the plates used in this study are 
3.4 % Aβ42, 5.8 % total tau (t-tau), and 6.8 % phosphorylated tau 181 (p-tau181181). Inter-
assay (plate to plate) coefficients of variation for a single CSF standard study are 8.3 % 
Aβ42, 6.9 % t-tau, 9.3 % p-tau181181.  
Statistical Analyses 
We conducted a series of risk factor comparisons of selected preoperative 
variables between those without delirium (no delirium group) and those with delirium 
(delirium group).  Student’s t-test was used for continuous variables and Fisher’s exact 
test was used for categorical or binary variables.  Age variable was examined both as a 
continuous variable and as a categorical variable (age categories: 7th decade ≥ 70 and < 
80; 8th decade ≥ 80 and < 90; 9th decade ≥ 90). MMSE was examined as a continuous 
variable and as a dichotomous variable (<24, ≥ 24), with ≥ 24 being considered as being 
in the normal range (43). Variables that were identified as independent risk factors (p ≤ 
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0.10) of postoperative delirium in the bivariate analysis and other variables from the 
literature were chosen for multivariable logistic regression. All analyses were conducted 
using STATA (StataCorp LP, College Station, TX). 
RESULTS:  
Baseline characteristics by postoperative delirium status 
The overall incidence of delirium was 41 %. The mean age was 85 years, and 
approximately 1/3 were men. Most of the subjects were relatively healthy cognitively 
with greater than 2/3 of the cohort with MMSE ≥ 24 and very few with global Clinical 
Dementia Rating (CDR) score of ≥ 1. However, those in the delirium group had 
significantly lower preoperative MMSE and higher CDR Sum of Boxes (CDR-SB). 
There were no differences in the mean CSF biomarker levels of Aβ42, t-tau, p-tau181 as 
well as Aβ42/t-tau or Aβ42/p-tau181 ratios between the two groups (Table IV.2).  
Baseline characteristics by postoperative delirium status including subsyndromal delirium 
 When subsyndromal delirium cases were added to the delirium cases, the 
incidence of delirium increased to 58 %. The preoperative characteristics between the 
delirium and no delirium groups remained similar except for those with delirium had 
significantly higher proportions of individuals with higher global CDR scores as well as 
significantly higher proportion of individuals with MMSE ≤ 24. There were no 
differences in the mean CSF biomarker levels of Aβ42, t-tau, p-tau181 as well as Aβ42/t-




Association of preoperative risk factors with postoperative delirium  
In the bivariate analysis, preoperative MMSE and global CDR, CDR-SB were the 
only significant risk factors (Table IV.4). In the multivariable analysis, none of the 
variables remained significant (Table IV.5).  
Association of CSF biomarkers with postoperative delirium by age categories  
 As the overall levels of CSF biomarkers were not significantly different between 
the delirium and no delirium groups, the data were stratified by age (decades). Although 
most subgroups did not show differences in the biomarker levels by delirium status, those 
in the 7th decade had lower preoperative levels of CSF Aβ42 in the delirium group 
compared to the no delirium group, albeit statistically not significant (Figure IV.1 and 
Table IV.6). Similar analysis was performed with CSF levels of t-tau and p-tau181, but 
there were no differences between the two groups in any age subgroup (data not shown).  
 Association of CSF biomarkers with preoperative MMSE by age categories 
 Due to the fact that CSF biomarkers may be a better correlate of underlying 
cognitive function in younger (7th decade) patients, we performed an age stratified 
analysis examining the association between the preoperative levels of CSF biomarkers 
with preoperative cognitive MMSE scores. The CSF Aβ42 levels were significantly lower 
in those with lower (<24) MMSE group among the overall group and the 7th decade 






In this study, we found that preoperative CSF levels of Aβ42, t-tau, p-tau181, 
Aβ42/t-tau and Aβ42/p-tau181 ratios are not associated with postoperative delirium after hip 
repair surgery in a subsample of our study population.  Our results show that there are no 
statistically significant differences in the preoperative CSF levels of the aforementioned 
biomarkers between the delirium group and no delirium group.  However, we found that 
the CSF levels of Aβ42 in the delirium group was lower compared to the no delirium 
group in a younger subgroup of patients (7th decade).  In addition, the association of CSF 
levels of Aβ42 with baseline cognitive measure with MMSE was strongest in the same age 
group.  
Cognitive impairment is a well-known risk factor of postoperative delirium (60, 
76). In our study, there was a trend towards lower preoperative MMSE score being 
associated with postoperative delirium, but not CSF biomarkers of AD. Our finding is 
similar to findings from a previous study of CSF AD biomarkers for predicting 
postoperative delirium in hip fracture population (77). However, these findings remain 
surprising as AD is thought to be highly prevalent in older adults, up to about a third 
among adults 85 and older (78, 79). CSF biomarkers such as lower levels of Aβ42, higher 
levels of tau as well as their ratios have been shown to be well correlated with AD (31, 
32) and are now part of recommended diagnostic work up in different stages of AD 
including preclinical and mild cognitive impairment (MCI) stages (28-30).  
One of the reasons for the poor correlation of CSF biomarkers of AD and 
postoperative delirium may be that the association of these biomarkers with cognitive 
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function may become attenuated with advancing age.  One study showed that the 
association between AD pathology and dementia was strong at the age of 75, but was 
attenuated by age 95 (80). Another study of AD pathology by PET amyloid showed that 
amyloid (Aβ) positivity decreased with aging, especially in non-APOE4 carriers, 
suggesting that it was more helpful for AD diagnosis in earlier age (81). 
In fact, our findings in a small subgroup of hip fracture patients demonstrate that 
there may be an age effect of CSF biomarkers in predicting postoperative delirium. CSF 
Aβ42 levels are lower in the delirium group compared to the no delirium group among 70 
year olds. In addition, there is a significant correlation between the clinical measure of 
cognitive function (MMSE) and CSF Aβ42 among the same group, but not in the older 
age groups.  
There are several limitation to this study. As this is an on-going randomized 
clinical trial, the intervention (light vs. heavy sedation) has not been unblinded, and 
therefore further analysis will need to be done once the treatment groups become known. 
The sample size is small as the CSF analysis was done on a subset of the cohort. Only 
limited clinical risk factors were examined due to the nature of the clinical trial.  
 The strengths of the study include the ability to examine the association between 
CSF biomarkers of AD and delirium in older adults including those in the 90’s, which 
may allow further exploration of age effect on different CSF biomarkers. The outcome 
ascertainment of delirium is also a strength as it is very comprehensive in assessment and 
duration, and therefore is less likely to have missed an incident delirium.  
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 Future studies will include association of CSF biomarkers with delirium severity 
as well as duration. In addition, plasma samples that were collected at the same time as 
CSF will be invaluable in allowing examination of peripheral vs. central biomarkers in 
delirium research. Current findings will also lead to future research into other non-AD 
























Table IV.1. Delirium diagnostic criteria  
Criterion Description of each criterion 
Criterion 1 Disturbance in Consciousness: (reduced clarity of awareness of the 
environment) with reduced ability to focus, sustain, or shift attention. 
Criterion 2 Change in Cognition: (such as memory deficit, disorientation, language 
disturbance) or the development of a perceptual disturbance that is not 
better accounted for by a preexisting dementia. 
Criterion 3 Disturbance develops over a short period of time (usually hours to days) 
and tends to fluctuate during the course of the day. 
 
Delirium diagnosis was given by the Consensus Diagnostic Committee (CDC) if all three 
criteria are met. Subsyndromal delirium diagnosis was given if there is no delirium, but if 





























Demographics     
Age-years, mean  (SD) 85       (7.3)     84       (7.3) 86      (7.4)   0.34 
Male, n (%) 24       (28.9) 14       (29.2) 10      (28.6) 0.95 
Race, n (%) 3         (3.6) 2         (4.2) 1        (2.9) 0.68 
Education    0.14 
  Elementary 20       (24.1) 9        (18.8) 11     (31.4)  
  High School  46       (55.4) 31      (64.6) 15     (42.9)  
  College 17       (20.5) 8        (16.7) 9       (25.7)  
     
Cognitive Measures     
MMSE*, mean (SD) 24.7    (3.7) 25.5    (3.6) 23.6    (3.53) 0.02 
  MMSE < 24, n (%) 27       (32.5) 13       (27.1) 14       (40.0) 0.22 
  MMSE ≥ 24, n (%) 56       (67.5) 35       (72.9) 21       (60.0)  
CDR Global, N, (%)     
  0 44       (53) 30       (62.5) 14       (40.0) 0.17 
  0.5 34       (41) 16       (33.3) 18       (51.4)  
  1 4         (5) 2         (4.2) 2         (5.7)  
  2 1         (1) 0         (0) 1         (2.9)  
CDR Sum of Boxes  
mean (SD) 
0.98    (1.76) 0.58    (1.08) 1.54    (2.33) 0.04 
     
CSF Laboratory  
Measures b 
    
Amyloid-beta 42 (Aβ42) 
mean (SD) 
355.15(137.79)      346.74(140.67) 367.28(134.68) 0.50 
total tau, mean (SD) c 85.39  (42.56) 84.55  (42.07) 86.51  (43.79) 0.84 
p-tau181, mean (SD) d 23.97  (11.85) 23.48  (10.15) 24.31  (14.00) 0.76 
Aβ42/t-tau (SD) 5.25    (3.07) 5.15    (2.96) 5.38    (3.24) 0.74 
Aβ42/p-tau181 (SD) 20.01  (12.47) 19.16  (11.68) 21.15  (13.57) 0.49 
     
 
a MMSE <15 excluded from the study; b CSF measures of amyloid-beta 42 (Aβ42), total 
tau (t-tau) and phosphorylated tau (p-tau181) are in the units of pg/ml. c1 missing value 
of CSF t-tau from the “No Delirium” group; d 4 missing values of CSF p-tau181 from the 
“No Delirium” group and 2 from “Delirium” group (missingness of both t-tau and p-
tau181 are due to the biomarker values being out of the range of detection limit).  
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Demographics     
Age-years, mean  (SD) 85       (7.3) 84       (7.23) 86       (7.4)   0.23 
Male, n (%) 24       (28.9) 9         (26.5) 15       (30.6)   0.68 
Race, n (%) 3         (3.6) 2         (5.9) 1         (2.0)   0.46 
Education     
  Elementary 20       (24.1) 6         (17.6) 14       (28.6)   0.49 
  High School 46       (55.4) 21       (61.8) 25       (51.0)  
  College 17       (20.5) 7         (20.6) 10       (20.4)  
     
Cognitive Measures     
MMSE, mean (SD) 24.7    (3.7) 26.4    (3.4) 23.4    (3.4) <0.001 
  MMSE < 24, n (%) 27       (32.5) 6         (17.6) 21       (42.9)   0.02 
  MMSE ≥ 24, n (%) 56       (67.5) 28       (82.4) 28       (57.1)  
CDR Global, N, (%)     
  0  44       (53) 25       (73.5) 19       (38.8)   0.01 
  0.5  34       (41) 7         (20.6) 27       (55.1)  
  1 4         (5) 2         (5.9) 2         (4.1)  
  2 1         (1) 0         (0) 1         (2)  
CDR Sum of Boxes  
mean (SD) 
0.98    (1.76) 0.51    (1.18) 1.30    (2.02)   0.03 
     
CSF Laboratory  
Measures  
    
Amyloid-beta 42 (Aβ42) 
mean (SD) 
355.15(137.79)    362.96(130.48) 
 
349.74(143.73) 0.67 
total tau, mean (SD)  85.39  (42.56) 83.94  (37.60) 86.40  (46.11) 0.80 
p-tau181, mean (SD)  23.97  (11.85) 23.71  (10.22) 23.92  (12.97) 0.94 
Aβ42/t-tau (SD) 5.25    (3.07) 5.22    (2.92) 5.26    (3.19) 0.94 
Aβ42/p-tau181 (SD) 20.01  (12.47) 1.98    (11.04) 1.98    (13.47) 0.86 
     
 







Table IV.4.  Bivariate analysis of preoperative risk factors for postoperative 
delirium 
 Total (N=83)  
   
Risk Factors Odds Ratio  
(95% CI) 
P-value 
Demographics & BMI   
   Age-years a 1.03 (0.97, 1.09)   0.34 
   Gender  1.03 (0.39, 2.69)   0.95  
   Race 0.58 (0.08, 3.97)   0.58 
   Education  0.90 (0.62, 1.29)   0.56 
      
Cognitive Measures   
   MMSE 0.86 (0.76, 0.98)   0.02 
   MMSE (<24, ≥ 24) 1.79 (0.71, 4.54)   0.22 
   CDR Global 4.25 (1.02, 17.64)   0.05 
   CDR Sum of Boxes 1.42 (1.02, 1.97)   0.04 
   
CSF Laboratory Measures   
   Amyloid-beta 42 (Aβ42) 1.00 (0.99, 1.00)   0.50 
   total tau 1.00 (0.99, 1.01)   0.84 
   p-tau181 1.01 (0.97, 1.05)   0.76 
   Aβ42/t-tau 1.02 (0.89, 1.18)   0.74 
   Aβ42/p-tau181 1.01 (0.98, 1.05)   0.49 
   
 













Table IV.5 Multivariable analysis of preoperative risk factors for postoperative 
delirium 
 Total (N = 83) 
 
 
Risk Factors Odds Ratio 
(95% CI) 
P-value 
Age 1.03 (0.94, 1.08)   0.83 
Gender 1.32 (0.46, 3.76)   0.61 
Race 0.42 (0.05, 3.64)   0.43 
Education 1.29 (0.80, 2.10)   0.30 
MMSE 0.84 (0.71, 1.01)   0.06 a 
CDR-Global 2.26 (0.44, 11.69)   0.33 
   














Figure IV.1. Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by 
delirium status  
 
Comparison of CSF Aβ42 levels between the groups that did not experience postoperative 
delirium “No delirium” and those that did “Delirium.” (A) Overall group; (B) 7th decade; 








Table IV.6. Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by 
delirium status 
  





     
Age groups  
(decades) 
Total No Delirium Delirium  
     
Overall  
No delirium N = 48a 
     Delirium N = 35 
 







  7th  
No delirium N = 13 









  8th  
No delirium N = 19 









  9th  
No delirium N = 15 










a.One subject was in the 6th decade. Stratification of age by decades demonstrated that 
mean CSF Aβ42 in those with postoperative delirium was lower compared to those 
without only among those in the 7th decade, although it did not reach a statistical 











Figure IV.2. Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by 
MMSE status 
 
Comparison of CSF Aβ42 levels between the “Higher MMSE” (MMSE ≥ 24) and “lower 
MMSE” (MMSE < 24) (A) Overall group; (B) 7th decade; (C) 8th decade; (D) 9th decade. 
There were no significant differences in the CSF Aβ42 levels between the Higher MMSE 








Table IV.7. Age stratified comparison of CSF amyloid-beta 42 (Aβ42) levels by 
MMSE status 
  





     
Age groups  
(decades) 









     
Overall  
Higher MMSE N=57a 
Lower MMSE  N=27 
 







  7th  
Higher MMSE N=20 









  8th  
Higher MMSE N=20 









  9th  
Higher MMSE N=16 










a.One subject was in the 6th decade. Lower CSF Aβ42 is thought to be associated with 














Appendix 1. Search terms for Chapter II 
Hand-searched journals  
Acta Anaesthesiologica Scandinavica,  Age and Ageing,  Anaesthesia  Anesthesia and 
Analgesia, Anesthesiology, Canadian Journal of Anaesthesia, Clinical Orthopaedics and 
Related Research, Dementia and Geriatric Cognitive Disorders, Gerontology, 
International Journal of Geriatric Psychiatry, International Psychogeriatrics, Journal of 
Bone and Joint Surgery, Journal of the American Geriatrics Society (JAGS), Journals of 
Gerontology, New England Journal of Medicine, and the Journal of the American 
Medical Association    
Hand-searched journal supplements  
Anesthesiology, Acta Anaesthesiologica Scandinavica, Canadian Journal of Anaesthesia, 
JAGS, and Psychogeriatrics 
PubMed Search Strategy 
#1 “hip fractures” [mh] OR hip fracture* [All Fields] OR "hip" [mh] OR "hip" [All 
Fields] OR Subtrochanteric Fracture* [All Fields] OR Trochanteric Fracture* [All 
Fields] OR Intertrochanteric Fracture* [All Fields] OR “Femoral Neck Fractures” 
[mh] OR femoral neck fracture* [All Fields] OR Femur Neck Fracture* [All 
Fields] 
#2 “delirium” [mh] OR “delirium” [All Fields] OR “delirium, dementia, amnestic, 
cognitive disorders” [mh]  OR organic mental disorder* [All Fields] OR 
“traumatic psychosis” [All Fields] OR “nonpsychotic organic brain syndrome” 
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[All Fields] OR ("mental disorders"[mh] AND ("1969/01/01"[PDAT] : 
"1974/12/31"[PDAT])) OR “Confusion” [mh] OR cognitive defect* OR cognitive 
disorder* OR cognitive deficit* OR “cognitive dysfunction” OR cognitive 
impairment* OR organic brain syndrome* OR organic brain disease* OR 
“disorientation” [All Fields] OR organic brain disorder* [All Fields] OR confus* 
[All Fields] OR delir* OR “psychosis” [All Fields] OR “Intraoperative 
complications” [mh] OR Intraoperative complication* [All Fields] OR intra-
operative complication* [All Fields] OR perioperative complication* [All Fields] 
OR peri-operative complication* [All Fields] 
#3 “Orthopedics” [mh] OR orthopedic* [All Fields] OR orthopaedic* [All Fields] 
OR “Surgical Procedures, Operative” [mh] OR operative procedure* [All Fields] 
OR “surgery” [All Fields] OR “surgery” [subheading] OR “surgeries” [All Fields] 
OR “surgical” [All Fields] OR surgi* [All Fields] OR “monitoring, 
intraoperative” [mh] OR “intraoperative monitoring” [All Fields] OR “intra-
operative monitoring” [All Fields] OR “intraoperative period” [mh] OR 
intraoperative period* [All Fields] OR intra-operative period* [All Fields] OR 
“intraoperative care” [mh] OR “intraoperative care” [All Fields] OR “intra-
operative care” [All Fields] OR “perioperative care” [All Fields] OR “peri-
operative care” [All Fields] 
#4 #1 AND #2 AND #3 
Embase Search Strategy 
72 
 
#1 'hip fracture'/exp OR 'hip fracture' OR 'hip fractures' OR 'femur subtrochanteric 
fracture'/exp OR subtrochanteric NEAR/2 fracture* OR 'femur intertrochanteric 
fracture'/exp OR intertrochanteric NEAR/2 fracture* OR 'femur fracture'/exp OR 
femoral NEAR/2 fracture* OR 'trochanteric fracture' OR 'trochanteric fractures' 
OR 'hip'/exp OR 'hip': ab, ti 
#2 'delirium'/exp OR delirium OR 'cognitive defect'/exp OR 'cognitive defect' OR 
'cognitive defects' OR 'cognitive disorder' OR 'cognitive disorders' OR 'cognitive 
deficit' OR 'cognitive deficits' OR 'cognitive dysfunction' OR 'cognitive 
impairment' OR 'cognitive impairments' OR 'organic mental disorder' OR 'organic 
mental disorders' OR 'traumatic psychosis' OR 'nonpsychotic organic brain 
syndrome' OR 'organic brain syndrome'/exp OR 'organic brain syndrome' OR 
'organic brain disease' OR 'confusion'/exp OR confusion OR 'disorientation' OR 
'organic brain disorder' OR 'organic brain disorders' OR confus* OR delir* OR 
'psychosis'/exp OR 'psychosis' OR intraoperative AND ('complication'/exp OR 
complication) OR 'intraoperative complication' OR 'intraoperative complications' 
OR 'intra-operative complication' OR 'intra-operative complications' OR 
'perioperative complication' OR 'perioperative complications' OR 'peri-operative 
complication' OR 'peri-operative complications' 
#3 'orthopedics'/exp OR 'orthopedic' OR 'orthopedics' OR 'orthopaedic' OR 
'orthopaedics' OR 'orthopedic surgery'/exp OR 'surgery'/exp OR 'surgery' OR 
surgi* OR 'operative procedure' OR 'operative procedures' OR 'intraoperative 
period'/exp OR 'intraoperative period' OR 'intraoperative periods' OR 'intra-
operative complication' OR 'intra-operative complications' OR 'perioperative 
73 
 
period'/exp OR 'perioperative period' OR 'perioperative periods' OR 'perioperative 
complication'/exp OR 'perioperative complication' OR 'perioperative 
complications' OR 'peri-operative complication' OR 'peri-operative complications' 
#4 #1 AND #2 AND #3 
PsycINFO Search Strategy 
S1 DE "Hips" OR hip fracture* OR femoral neck fracture* OR hip OR hips  
S2 DE "Delirium" OR DE "Organic Brain Syndromes" OR organic brain syndrome* 
OR organic mental disorder* OR DE "mental confusion" OR DE "cognitive 
impairment" OR cognitive impairment* OR cognitive defect* OR cognitive 
disorder* OR cognitive deficit* OR "cognitive dysfunction" OR organic brain 
disease* OR disorientation OR organic brain disorder* OR confus* OR delir* OR 
DE "psychosis" OR psychosis  
S3 Orthopedics OR orthopedic OR operative procedure* OR DE "surgery" OR 
surgery OR surgeries OR surgi*  
S4 S1 AND S2 AND S3 
CINAHL Search Strategy 
S1 (MM "Hip") OR hip* OR (MM "Hip Fractures, Stress") OR (MM "Hip 
Fractures") 
OR (MM "Hip Surgery") OR subtrochanteric fracture* OR trochanteric fracture* 
OR femoral neck fracture* OR (MM "femur neck") OR femur neck fracture* 
74 
 
S2 (MM "Delirium") OR (MM "Delirium, Dementia, Amnestic, Cognitive 
Disorders") OR (MM "Organic Mental Disorders") OR (MM "Confusion") OR 
(MM "Acute Confusion (NANDA)") OR (MM "Cognition Disorders") OR (MM 
"Intraoperative Complications") OR (MM "Intraoperative Care") OR confus* OR 
delir* OR organic mental disorder* OR cognitive defect* OR cognitive disorder* 
OR cognitive deficit* OR "cognitive dysfunction" OR cognitive impairment* OR 
organic brain syndrome* OR organic brain disease* OR disorientation OR 
organic brain disorder* OR intraoperative complication* OR intraoperative care 
OR intra-operative complication* OR intra-operative care OR perioperative 
complication* OR peri-operative complication* 
S3 (MM "Orthopedics") OR orthopedic* OR orthopaedic* OR (MM "Orthopedic 
Surgery") OR (MM "Hip Surgery") OR (MM "Surgery, Operative") OR surgi* 
OR operative procedure* OR “surgery” OR "surgeries" OR “intraoperative 
monitoring” OR “intraoperative period” OR “intraoperative care” 
S4 S1 AND S2 AND S3 
Cochrane Library Search Strategy 
#1 MeSH descriptor: [Hip Fractures] explode all trees 
#2 MeSH descriptor: [Arthroplasty, Replacement, Hip] explode all trees 
#3 intra-articular fracture* or periprosthtic fracture* or hip* or femoral neck 
fractures or subtrochanteric fracture* or trochanteric fracture* or intertrochanteric 
fracture* or femur neck fracture*:ti,ab,kw  
#4 #1 or #2 or #3  
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#5 MeSH descriptor: [Delirium] explode all trees 
#6 MeSH descriptor: [Delirium, Dementia, Amnestic, Cognitive Disorders] explode 
all trees 
#7 MeSH descriptor: [Confusion] explode all trees 
#8 organic mental disorder* or confus* or disorientation or "organic brain disorder" 
or "organic brain disorders" or delir* or "psychosis" or "intraoperative 
complications" or "intraoperative complication" or "intra-operative complication" 
or "intra-operative complications" or "perioperative complication" or 
"perioperative complication" or "peri-operative complications" or "peri-operative 
complications":ti,ab,kw  
#9 MeSH descriptor: [Intraoperative Complications] explode all trees 
#10 #5 or #6 or #7 or #8 or #9  
#11 MeSH descriptor: [Orthopedics] explode all trees 
#12 MeSH descriptor: [Surgical Procedures, Operative] explode all trees 
#13 MeSH descriptor: [Intraoperative Period] explode all trees 
#14 MeSH descriptor: [Intraoperative Care] explode all trees 
#15 MeSH descriptor: [Perioperative Period] explode all trees 
#16 MeSH descriptor: [Perioperative Care] explode all trees 
#17 MeSH descriptor: [Monitoring, Intraoperative] explode all trees 
#18 Orthopedic* or orthopaedic* or "operative procedure" or "operative procedures" 
or surgery or surgeries or surgi* or "intraoperative monitoring" or "intra-operative 
monitoring" or "intraoperative period" or "intra-operative period" or 
"intraoperative care" or "intra-operative care" or "intraoperative period" or "intra-
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operative period" or "perioperative period" or "peri-operative period" or 
"perioperative care" or "peri-operative care":ti,ab,kw  
#19 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18  
#20 #4 and #10 and #19 
Hand Search Strategy 
“Subtrochanteric Fracture,” “Trochanteric Fracture,”  “Intertrochanteric Fracture,”  
“Femoral Neck fracture”  
“confusion,” “disorientation” 
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 Project 2 (Troncoso, Project Leader) 
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Clinical Focus  
 
My main clinical focus at the Johns Hopkins Memory and Alzheimer’s Treatment Center 
(JHMATC) is evaluation and treatment of cognitive impairment and associated disorders 
including, but not limited to the following disorders.  
 
• Mild Cognitive Impairment (MCI), Alzheimer’s dementia (AD), Dementia of Lewy 
Bodies (DLB), Frontotemporal dementia (FTD) 
• Preoperative cognitive assessment 
• Postoperative cognitive dysfunction (POCD) 
• Behavioral and psychological symptoms of dementia (BPSD) 
• Delirium  
• Multi-morbidity and polypharmacy associated with cognitive disorders 
 
My clinical role as a clinician in the Division of Geriatric Medicine and Gerontology also 
includes, but not limited to the following: 
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• Perioperative consultation  
• Evaluation and treatment of patients in the Specialty Hospitals at the Johns 
Hopkins Bayview Medical Center (JHBMC)  
• Evaluation and treatment of patients on the in-patient general internal medicine 
units at the Johns Hopkins Bayview Medical Center (JHBMC) 
 
 
Medical, other state/government licensure 
2003 – present Maryland # D60628 
 
Boards, other specialty certification 
2013        American Board of Internal Medicine Maintenance of Certification 
(MOC)  
2014 American Board of Geriatric Medicine Maintenance of Certification 
(MOC) 
 
Clinical Service Responsibilities 
 
2005 – present Internal Medicine Service, Attending Physician, Johns Hopkins 
Bayview Medical Center (JHBMC), 4 weeks per year (2 week 
rotations) 
 
Clinical Program Building/Leadership 
 
2008 – present Associate Director, The Johns Hopkins Memory and Alzheimer’s 
Treatment Center (JHMATC).  In my capacity, I am responsible for 
overseeing the clinical operation at the JHMATC along with the 
Director and the Co-Directors.  
 
01/08 – 06/10 Assistant Medical Director, Medical Behavior Unit (MBU), Johns 
Hopkins Bayview Medical Center Specialty Hospitals  
 
 
EDUCATIONAL ACTIVITIES  
 




My main educational focus is on evaluation and treatment of cognitive impairment and 
associated disorders, encompassing learners from medical school, residency, 
postdoctoral fellowship, as well as physicians and caregivers. These educational 
activities vary from individual instructions in clinic settings to larger Continuing Medical 






2001 – 2002 Instructor, internal medicine residents, ambulatory curriculum, 
University of Illinois at Chicago (UIC), Chicago, IL. 
2001 – 2002 Instructor, third year medical students, ambulatory curriculum, Jesse 
Brown VA Medical Center (formerly the West Side VA Medical 
Center) rotation, University of Illinois at Chicago (UIC), Chicago, IL. 
2001 – 2002 Instructor, third year medical students, monthly lectures on “Asthma” 
and “Diabetes,” University of Illinois at Chicago (UIC), Chicago, IL. 
 
2001 – 2002 Instructor, third year medical students, monthly lectures on 
“Dementia” and visit to the Alzheimer's Family Day Care Center, 
University of Illinois at Chicago (UIC), Chicago, IL. 
2009 Instructor, physicians participating in the Johns Hopkins Division of 
Geriatric Medicine and Gerontology Mini-Fellowship, Baltimore, MD 
2014 – present Faculty discussant, postdoctoral fellows, Journal Club, Johns Hopkins 





2005 – present Attending physician, internal medicine residents, Johns Hopkins 
Bayview Medical Center, Baltimore, MD.  
2005 – 2008  Attending physician, medical students and residents, Geriatric 
Psychiatry Memory Clinic, Johns Hopkins Hospital, Baltimore, MD.  
2005 – 2006 Attending physician, medical students, residents and postdoctoral 
fellows, Terrace Rehabilitation, Johns Hopkins Bayview Medical 
Center, Baltimore, MD.  
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2007 Attending physician, medical students, residents and postdoctoral 
fellows, Hip Fracture Consult Service, Johns Hopkins Bayview 
Medical Center, Baltimore, MD. 
2007 – 2008 Attending physician, Chesapeake Chronic Medical Unit, medical 
students and postdoctoral fellows, Johns Hopkins Bayview Medical 
Center, Baltimore, MD.   
2008 – 2010 Attending physician, Medical Behavior Unit (formerly - Medical 
Psychiatry Unit), medical students and postdoctoral fellows, Johns 
Hopkins Bayview Medical Center, Baltimore, MD. 
2008 – present Attending physician, medical students, residents and postdoctoral 
fellows, the Johns Hopkins Memory and Alzheimer’s Treatment 






04/12/08 Plenary Speaker, physicians and allied health care workers, 
“Diabetes, Insulin Resistance and Dementia: New Therapeutic 
Avenues?,” 14th Annual Update on the Treatment of Alzheimer’s and 
Related Disorders, Johns Hopkins University Department of 
Psychiatry and Behavioral Sciences CME, Baltimore, MD. 
02/04/10 Instructor, physicians and allied health care workers, “Update on 
Dementia: What’s on the Horizon,” Edmund G. Beacham 37th Annual 
Current Topics in Geriatrics, Johns Hopkins University Division of 
Geriatric Medicine and Gerontology CME, Baltimore, MD. 
04/10/10 Instructor, physicians and allied health care workers, “Medical Co-
morbidity in Dementia Care,” 16th Annual Update on The Treatment 
of Alzheimer’s and Related Disorders, Johns Hopkins University 
Department of Psychiatry and Behavioral Sciences CME, Baltimore, 
MD. 
04/02/11 Instructor, physicians and allied health care workers, “Using 
Cholinesterase Inhibitors and Memantine in Non-AD Dementia: Pros 
and Cons,” 17th Annual Update on the Treatment of Alzheimer’s and 
Related Disorders, Johns Hopkins University Department of 
Psychiatry and Behavioral Sciences CME, Baltimore, MD. 
02/15/13 Instructor, physicians and allied health care workers, “Update on 
Dementia: What’s on the Horizon,” Edmund G. Beacham 40th Annual 
Current Topics in Geriatrics, Johns Hopkins University Division of 
Geriatric Medicine and Gerontology CME, Baltimore, MD. 
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04/13/13 Instructor, physicians and allied health care workers, “Handling After 
Hour Calls from Patients and Caregivers,” 19th Annual Update on the 
Treatment of Alzheimer’s and Related Disorders, Johns Hopkins 
University Department of Psychiatry and Behavioral Sciences CME, 
Baltimore, MD. 
02/15/14 Instructor, physicians and allied health care workers, “Screening for 
Dementia in the Office,” Edmund G. Beacham 41th Annual Current 
Topics in Geriatrics, Johns Hopkins University Division of Geriatric 
Medicine and Gerontology CME, Baltimore, MD. 
04/12/14 Instructor and Chair of the Plenary Panel on Agitation and Its 
Management, physicians and allied health care workers, “Helping the 
Patients with Dementia Decide When and How to Stop Driving,” 20th 
Annual Update on the Treatment of Alzheimer’s and Related 
Disorders, Johns Hopkins University Department of Psychiatry and 
Behavioral Sciences CME, Baltimore, MD..  
02/26/15 Instructor, physicians and allied health care workers, “Is This 
Delirium?” Johns Edmund G. Beacham 42nd Annual Current Topics 
in Geriatrics, Johns Hopkins University Division of Geriatric Medicine 
and Gerontology CME, Baltimore, MD. 
03/05/16 Instructor, physicians and allied health care workers, “Scan or not to 
Scan: Imaging Dementia-Evidence for Amyloid Scanning” Johns 
Edmund G. Beacham 43rd Annual Current Topics in Geriatrics, Johns 
Hopkins University Division of Geriatric Medicine and Gerontology 







11/01/08 Presenter, patients and caregivers, “Tips to Manage Alzheimer’s,” 
Journey to Hope Conference, Johns Hopkins University Bayview 
Medical Center, Baltimore, MD. 
10/31/09 Presenter, patients and caregivers, “Sleeping, Eating and Bathroom 
Issues in Dementia,” Journey to Hope Conference, Johns Hopkins 
University Bayview Medical Center, Baltimore, MD. 
02/19/10 Presenter, patients and caregivers, “Sleeping, Eating and Bathroom 
Issues in Dementia,” Baltimore Commissions on Aging and 
Retirement Education Caregiver Conference, Baltimore, MD. 
05/15/13 Presenter, Korean seniors, Waxter Wisdom Memory Loss 
Presentation, Greenmount Senior Center, Baltimore, MD 
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07/25/14 Presenter, caregivers, “Driving Issues in Dementia,” Caregiver 
Education Seminar, the Johns Hopkins Memory and Alzheimer’s 
Treatment Center, Baltimore, MD. 
11/08/14 Presenter, patients and caregivers, “Future Directions in Alzheimer’s 
Disease Care and Research,” Journey to Hope Conference, Johns 
Hopkins University Bayview Medical Center, Baltimore, MD. 
10/23/15 Presenter, postdoctoral fellows, “Diagnosing Delirium at Home” 
Caregiver Education Seminar, Johns Hopkins University, Department 
of Psychiatry and Behavioral Sciences, Baltimore, MD. 
01/30/14 Instructor, postdoctoral fellows, “Helping the Patient with Dementia 
Decide When and How to Stop Driving,” Geriatric and 
Neuropsychiatric noon seminar. Johns Hopkins University School of 
Medicine, Baltimore, MD. 
05/08/15 Instructor, postdoctoral fellows, “3D CAM” Geriatric and 
Neuropsychiatric noon seminar. Johns Hopkins University School of 
Medicine, Baltimore, MD. 
01/11/16 Presenter, biomarker researchers at the Johns Hopkins University, 
“Standardization of Biomarkers,” Johns Hopkins Alzheimer’s Disease 
Research Center Workgroup  




05/07 – 07/07 Amanda Smith, MD, medical student, Creighton University School of 
Medicine, Omaha, NE, present position – attending physician, 
Pediatric Partners, Bel Air, MD. 
07/07 – 08/07 Julie King, MD, medical student, Johns Hopkins University School of 
Medicine, Baltimore, MD, present position – attending physician, 
Pavilion Pediatrics, Johns Hopkins at Green Spring Station, 
Lutherville-Timonium, MD; publication - manuscript # 4 
06/09 – 08/09 Katherine Abalos, MD, medical student, University of Virginia, 
Charlottesville, VA,   
present position – attending physician, Beth Israel Deaconess 
Hospital, MA; poster presentation at the 2010 Annual Scientific 
Meeting, American Geriatrics Society (poster #10) 
07/10 – 08/10 Daniel Parker, MD, medical student, Eastern Virginia Medical School, 
Norfolk, VA,  
present position –  Internal medicine resident, Eastern Virginia 
Medical School, VA; 
Award - Presidential Poster Session, 2011 Annual Scientific Meeting, 




06/11 – 07/11 Carly Fabrizio, medical student, Rowan University, New Jersey 
School of Osteopathic Medicine, NJ; poster presentation at the 2012 
Annual Scientific Meeting, American Geriatrics Society (poster #14) 
06/12 – 08/12 Cathy Chen, undergraduate summer research student, Princeton 
University, Princeton, NJ, present position - 2nd year Medical student, 
University of Mississippi School of Medicine, Jackson, MS; publication 
- manuscript #11 
06/12 – 07/12 Shayna Shackford, medical student, University of New England in 
Maine, Biddeford, ME; Award - Presidential Poster Session, 2013 
Annual Scientific Meeting, American Geriatrics Society (poster #17) 
 
06/14 – 08/14 Jessica Zimmerman, medical student, Eastern Virginia Medical 
School, Norfolk, VA, current position - medical student, Eastern 
Virginia Medical School; poster presentation at the 2015 Annual 
Scientific Meeting, American Geriatrics Society (poster #21) 
 
06/15 – present Megan Donnelly, undergraduate student, Department of 
Neuroscience in the Krieger School of Arts and Sciences, Johns 
Hopkins University, Baltimore, MD.  
 
06/15 – 08/15 Samantha Mayhew, medical student, University of Cincinnati College 
of Medicine, Cincinnati, OH; Abstract accepted for the 2016 Annual 




10/11 – 06/14 Ying Liu MD, PhD, Senior Research Specialist, Department of 
Pathology, the Johns Hopkins University School of Medicine, 
Baltimore, MD, present position - Assistant Professor, Department of 
Neurology, the Johns Hopkins School of Medicine, Baltimore, MD; 
publication – manuscript # 6 
 
02/12 – 04/14 Tolulope Fafowora, MD MBA, Postdoctoral fellow, Department of 
Medicine, Division of Geriatric Medicine and Gerontology, the Johns 
Hopkins School of Medicine, Baltimore, MD; publication - manuscript 
# 11 
 
07/13 – 06/14 Monica Sandoval, MD, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD, present position – attending 
physician, Greater Baltimore Medical Center, Baltimore, MD 
07/13 – 06/14 Jessica Lee, MD MS, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD, present position –Assistant 
Professor, Geriatrics and Palliative Medicine, The University of Texas 
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Health Sciences Center at Houston, Houston, TX; publication – 
manuscript #14 
 
07/13 – present  Halima Amjad MD MPH, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD, currently postdoctoral fellow, the 
Johns Hopkins School of Medicine; publication – editorial #1. 
 
02/14 – 06/15 Olivia Nirmalasari MD, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD, present position – attending 
physician, Providence ElderPlace PACE (Program of All Inclusive 
Care for the Elderly); poster presentation at the 2015 Annual Scientific 
Meeting, American Geriatrics Society (poster #20) 
07/14 – 06/15 Jennifer Gabbard MD, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD, present position – Assistant 
Professor in Section of Gerontology and Geriatrics; Associate 
Program Director of Hospice and Palliative Medicine, Wake Forest 
University School of Medicine. Winston Salem, North Carolina; 
publication -  
web publication #3 
 
07/14 – present Stefan David MD, Postdoctoral fellow, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD; publication - web publication #3 
 
07/14 – present Mia Yang MD, Postdoctoral fellow, Department of Medicine, Division 
of Geriatric Medicine and Gerontology, the Johns Hopkins School of 
Medicine, Baltimore, MD.  
 
11/14 – present Sara Mamo AuD PhD, Postdoctoral fellow, Department of 
Otolaryngology-Head and Neck Surgery, the Johns Hopkins School of 
Medicine, Baltimore, MD, present position – Instructor, Department of 
Otolaryngology-Head and Neck Surgery, the Johns Hopkins School of 
Medicine, Baltimore, MD; publications – review articles #2 and 3; 
awards - New Investigator Research Grant, American Academy of 
Audiology 
 
12/14 – present Aisha Harun MD, Resident, Department of Otolaryngology-Head and 
Neck Surgery, the Johns Hopkins School of Medicine, Baltimore, MD; 
Award - the American Academy of Otolaryngology-Head and Neck 
Surgery (AAO-HNSF) Resident Research Grant; poster accepted for 





07/15 – present Ariel Green, MD, MPH, Assistant Professor, Department of Medicine, 
Division of Geriatric Medicine and Gerontology, the Johns Hopkins 
School of Medicine, Baltimore, MD 
 
 
Educational Program Building/Leadership 
 
2007 – 2008 Associate Program Director, Medical Student Training in Aging 
Research. 
 
2007 – present Member, Application Selection Committee, Medical Student Training 
in Aging Research. 
 
2010 – 2013 Member, Planning Committee, Update on the Treatment of 
Alzheimer’s Disease and Related Disorders (CME). 
 
2011 – present Member, Medical Student Training in Aging Research (MSTAR) 
Application Selection Committee, Subcommittee for Ensuring 
Diversity, Johns Hopkins University School of Medicine. 
 
2011 – present   Director (2014-present), Co-director (2011-2014), Fellowship 
Professional Development Series, Johns Hopkins University School of 
Medicine 
 
2012 – present Faculty Director, Johns Hopkins Division of Geriatric Medicine and 
Gerontology Fellowship Dementia Morning Report, Johns Hopkins 









2012 – present  Chair, Adverse Event Consensus Panel, ADvance Clinical Study.  In 
my capacity, I am responsible for leading clinical events committee 
(CEC) composed of a geriatrician, neurologist and a neurosurgeon for 
the ADvance Clinical Study.  
 
2015 – present  Co-leader, Dementia Research Group, Division of Geriatrics and 
Gerontology. In my capacity, I am responsible for co-mentoring 
postdoctoral fellows and junior faculty who are interested in dementia 
research.  
 
Inventions, Patents, Copyrights 
 
02/20/15 Oh E, Craft S, Lyketsos C.  Methods for the identification, 









2008 – present Oral Glucose Tolerance Test for Alzheimer’s Disease 
 JHMI Protocol Number NA_00014837 
Role: Principal Investigator 
 
2011 – present Cerebrospinal fluid cytokines as biomarkers for delirium following hip 
fracture repair in elders 
 JHMI Protocol Number NA_00017021 
 Role: Principal Investigator 
 
2013 – present Therapeutic effects of intranasally-administered insulin 
adults with amnestic mild cognitive impairment (aMCI) or mild 
Alzheimer’s disease (AD) ADC-046-INI 
 JHMI Protocol Number NA_00014837 
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 Role: Principal Investigator 
 
2014 – present Targeted needs assessment for perioperative considerations for 
delirium prevention and management in elderly patients undergoing 
non-cardiac surgery.   
JHMI Protocol Number IRB00053099 
Role: Principal Investigator 
 
2015 – present Prevalence of age related hearing loss among vulnerable older adults 
with cognitive impairment   
JHMI Protocol Number IRB00064169 
Role: Principal Investigator 
 
2016– present Imaging in Dementia-Evidence for Amyloid Scanning (IDEAS) study 
JHMI Protocol Number IRB00090317   




2009 – present Serotonin Modulation in Mild Cognitive Impairment 
 JHMI Protocol Number NA_00026190 
 Role: Co-Investigator 
 
2011 – present A strategy to reduce the incidence of post-operative delirium in elderly 
patients 
 JHMI Protocol Number NA_00041873 
 Role: Co-Investigator 
 
2011 – present Insulin Resistance in Late-Life Depression  
 JHMI Protocol Number NA_00066410 
 Role: Co-Investigator 
 
2012 – present Advance Clinical Study 
JHMI Protocol Number 




2013 – present 3T MRI imaging of dementia patients during clinical care 
JHMI Protocol Number NA_00024337 
Role: Co-Investigator 
  
2013 – present Alzheimer’s disease anti-inflammatory prevention trial (ADAPT) 
JHMI Protocol Number NA_00041709 
Role: Co-Investigator  
 
2013 – present Insulin resistance in late-life depression 
JHMI Protocol Number NA_00066410 
Role: Co-Investigator  
 
2014 – present Providing Hearing Health Care to Patients with Cognitive Impairment 
JHMI Protocol Number IRB00036007 
Role: Co-Investigator 
 
2014 – present Skin biopsy for peripheral neuropathy 
JHMI Protocol Number IRB00036876 
Role: Co-Investigator 
 
2014 – present Investigation of vestibular reflexes 
JHMI Protocol Number IRB00035749 
Role: Co-Investigator 
 
2015 – present BDPP Treatment for Mild Cognitive Impairment (MCI)and prediabetes 
JHMI Protocol Number IRB00000062802 
Role: Co-Investigator 
 
2015 – present MIND: An RCT of care coordination for community-living persons with 
dementia 
JHMI Protocol Number IRB00041744 
Role: Co-Investigator 
 
2015 – present Comprehensive home-based dementia care coordination for 
Medicare-Medicaid Dual Eligibles in Maryland 





2015 – present Improving Communication for Persons with Dementia and Hearing 
Loss 






2011 – 2013 Examination of dementia patients and functional outcome 
 JHMI Protocol Number NA_00051361 
 Role: Principal Investigator 
 
2010 – 2015 Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarker Study 
 JHMI Protocol Number NA_0035050  




2007 – 2010 A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating 
Study to Evaluate the Safety, Tolerability, and Immunogenicity of 
V950 Formulated on Aluminum-Containing Adjuvant with or without 
Iscomatrix in Patients with Alzheimer’s Disease 
 JHMI Protocol Number NA_00009297  
 Role: Co-Investigator 
 
2008 – 2010 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study 
to Evaluate the Efficacy and Safety of Eighteen Months of Treatment 
with PF-04494700 (TTP488) in Participants with Mild to Moderate 
Alzheimer’s Disease 
 JHMI Protocol Number NA_00016662 
Role: Co-Investigator 
 
2008 – 2010 Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s 
Disease: LY450139 versus placebo                
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 JHMI Protocol Number NA_00018175  
 Role: Co-Investigator 
 
2008 – 2010 Phase III, Multicenter, Randomized, Double-Blind, Placebo 
Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab 
(AAB-001, ELN 115727) in Patients with Mild or Moderate Alzheimer’s 
Disease Who are Apolipoprotein E4 Carriers and Non-carriers 
 JHMI Protocol Number NA_00018175  





Institutional Administrative Appointments 
2001 – 2002  Member, House Staff Evaluation Committee, Department of Medicine, 
University of Illinois at Chicago  
2001 – 2002  Member, House Staff Council, Department of Medicine, University of 
Illinois at Chicago  
2001 – 2002  Member, Education Committee, Department of Medicine, University of 
Illinois at Chicago  
2005 – 2007  Member, Diagnostic Consensus Panel, Alzheimer’s Disease 
Research Center, Johns Hopkins University  
2008 – 2010  Committee Member, Women’s Task Force, Johns Hopkins University 
School of Medicine 
2010 – 2013 Member, Planning Committee for the Update on the Treatment of 
Alzheimer’s and Related Disorders, Peer Reviewer for Conflict of 
Interest 
2011 – 2012 Committee Member, SMART Strategic Goal: Building Community 





Editorial Board Appointments 




Journal Peer Review Activities 
2008 – present  Abstract reviewer, Neurological and Behavioral Sciences abstract 
review category, American Geriatrics Society Annual Scientific 
Meeting 
2009  Reviewer, the Journal of Alzheimer’s disease 
2011 – present Reviewer, the Journal of American Geriatrics Society 
2012 – present Protocol reviewer, Institute for Clinical and Translational Research 
(ICTR) Clinical Research Unit (CRU)  
2012 – present Reviewer, International Psychogeriatrics          
2012 – present Reviewer, PLOS One 
2013 – present Reviewer, Johns Hopkins Alzheimer’s Disease Research Center pilot 
grants 
2014 Reviewer, Alzheimer’s Research and Therapy 
2014  Reviewer, Reichel’s Care of the Elderly: Clinical Aspects of Aging (7th 
edition), Cambridge Press 
2015 Reviewer, Journal of Gerontology: Medical Sciences 
2015 Reviewer, Alzheimer’s & Dementia: The journal of the Alzheimer’s 
Association 
2016 – present Reviewer, International Journal of Geriatric Psychiatry 
 




1996 – present  Member, Christian Medical & Dental Associations 
2001 – present  Member, American Geriatrics Society 
2006 – present  Member, Society for Neuroscience 
2006 – present  Member, Special Interest Group (SIG) on Clinical Research in 
Dementia, American Geriatrics Society  
2008 – present Steering Committee Member, American Geriatrics Society Research 
Junior Faculty SIG Steering Committee 
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2010 – present Member, International College of Geriatric Psychoneuropharmacology 
2010 – present   Member, Alzheimer’s Association International Society to Advance 
Alzheimer’s Research and Treatment (ISTAART) 
2011 – present  Member, American Delirium Society 
2012 – present   Member, European Delirium Society 
2013 – present Executive Committee Member, International Society to Advance 
Alzheimer's Research and Treatment (ISTAART) Professional Interest 
Area (PIA) Perioperative Cognition 
2014 – present Member, American Geriatrics Society Research Junior Faculty 
Special Interest Group (SIG)  Research Methods Sub-committee. 
2015 – present Member, American Delirium Society Research Committee  
2015 – present Vice Chair, International Society to Advance Alzheimer's Research 
and Treatment (ISTAART) Professional Interest Area (PIA) 
Perioperative Cognition 
2015 – present Perioperative Cognition Professional Interest Area (PIA) nomenclature 
consensus working group  
 
RECOGNITION 
Awards and Honors  
1990 John A. Hartford Foundation Fellowship in Geriatric Medicine 
1991 de Kiewiet Summer Research Scholarship 
1992 Okayama University International Exchange Scholarship 
1995 National Institute of Health Summer Internship Program, National 
Institute of Neurological Disorders and Stroke (NINDS) 
2002 – 2005  National Institute on Aging Research Training (T32) in Gerontology 
and Geriatric Medicine 
2003 Technical Assistance Workshop, National Institute on Aging 
2005 Summer Institute on Aging Research, National Institute on Aging 
2006 Presidential Poster Session, Annual Scientific Meeting, American 
Geriatrics Society  
(Also received awards in 2007, 2010, 2011, 2013) 
2009 – 2011 The Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator 
Award in Alzheimer’s disease  
2010 Merck New Investigator Award 
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2010 – 2011 Johns Hopkins Clinical Research Scholars Junior Faculty KL2 Award  
2010 International College of Geriatric Psychoneuropharmacology Junior 
Investigator Award 
2011 Early Career Women Faculty Professional Development Seminar, 
Association of American Medical Colleges (AAMC) (competitive 
selection) 
2012 Johns Hopkins Emerging Women’s Leadership Program inaugural 
cohort (competitive selection) 
2012 Career Development Award recipient (K23), National Institute on 
Aging 
2013 Johns Hopkins Junior Faculty Leadership cohort (competitive 
selection) 
2013 Excellence in Teaching Award, Johns Hopkins School of Medicine, 
Division of Geriatric Medicine and Gerontology 
2014 American Geriatrics Society (AGS)/National Institute on Aging (NIA) 
U13 Conference Series attendee (Delirium in Older Adults: Finding 
Order in the Disorder) (competitive selection) 
2014 CEDARTREE Second Annual Delirium Bootcamp Travel Grant 
Recipient (competitive selection) 
2015 Johns Hopkins Leadership Program for Women Faculty (competitive 
selection) 




Invited Talks, Panels 
 
JHMI / Regional 
05/16/09 Presenter, Johns Hopkins University Dementia Retreat, “Attenuation 
of Monoaminergic Neurodegeneration by Immunotherapy,” Baltimore, 
MD 
03/06/10 Presenter, 3rd Annual Billie Showers Research Symposium, 
“Alzheimer's and Diabetes, Is There a Connection?,” Washington DC 
03/24/10 Presenter, Welch Center for Prevention, Epidemiology and Clinical 
Research, the Diabetes and Obesity Group, “Insulin Resistance and 
Alzheimer’s disease – Is there a Connection?,” Baltimore, MD 
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09/19/11 Presenter, Johns Hopkins University Delirium Consortium, 
“Biomarkers of Delirium,”  
Baltimore, MD 
09/28/11 Presenter, Willow Valley Retirement Community, “Journey of Hope: 
Perspectives and Progress on the Alzheimer’s Front,” Lancaster, PA 
11/08/11 Presenter, Johns Hopkins Health Care, “Dementias of Diabetes,” Glen 
Burnie, MD 
11/02/12 Presenter, Department of Medicine Grand Rounds, Johns Hopkins 
University, “CSF Biomarkers of Postoperative Delirium in Hip Fracture 
Patients,” Baltimore, MD 
06/05/13 Presenter, Abramson Center for Jewish Life, “Successful Aging: 
Preventing Your Risk for Developing Dementia,” North Wales, PA 
03/28/14 Panelist, Professional Development Office & Office of Faculty 
Development, Johns Hopkins Medical Institutions, “Writing Successful 
K application: Beyond the Basics,” Baltimore, MD  
02/04/15 Grand Rounds Speaker, Copper Ridge Institute, “Hearing Loss and 
Cognitive Impairment,” Sykesville, MD 
03/27/15 Grand Rounds Speaker, MedStar Harbor Hospital, “Delirium and 
Dementia,”  
Baltimore, MD 
04/20/15 Presenter, Johns Hopkins University Delirium Consortium, “Sex 
Differences in Hip Fracture Surgery Preoperative Risk Factors of 
Delirium and Postoperative Outcomes,” Baltimore, MD 
01/11/16 Presenter, Johns Hopkins Alzheimer’s Research Center Workgroup 
on Modeling Biomarkers, “Standardization of Biomarkers,” Baltimore, 
MD 
03/21/16 Presenter, Johns Hopkins University Dementia Consortium, “Oral 
Glucose Tolerance Test as a Biomarker Tool for Alzheimer’s disease 
 
National 
11/20/03 Presenter, National Institute on Aging, “Development of Serum 
Assays for Diagnosis of Pre-Clinical Alzheimer’s Disease.” Technical 
Assistance Workshop, San Diego, CA  
10/19/04 Presenter, The University of Chicago, Section of Geriatrics, “Passive 
Immunization and Alzheimer’s disease,” Chicago, IL 
06/09/05 Presenter, American Association of Neuropathologists 2005 Annual 
Meeting, “Passive immunization with monoclonal antibody Aβ 1-11 in 
transgenic mouse models of Alzheimer’s disease,”Washington DC 
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05/02/09 Presenter, American Geriatrics Society 2009 Annual Meeting Paper 
Session, “Immunotherapy Attenuates Monoaminergic 
Neurodegeneration in Transgenic Mice,”  
Chicago, IL 
06/08/10 Presenter, The Rosalinde and Arthur Gilbert Foundation/AFAR 
Meeting, “Oral Glucose Tolerance Test for Alzheimer’s disease 
Biomarker Development,”  
Santa Barbara, CA 
11/08/12 Presenter, Department of Anesthesiology & Critical Care, Weekly 
Research In Progress Seminar, Perelman School of Medicine, 
University of Pennsylvania, “Using CSF biomarkers of AD to Identify 
Patients at Risk for Postoperative Delirium,”  
Philadelphia, PA 
11/23/13 Presenter, Symposium: Persons With Cognitive Impairment in Studies 
After Hip Fracture: What Do We Know and What Can We Do?  
Annual Meeting, the Gerontological Society of America (GSA), 
“Dementia and Delirium after Hip Fracture: In-Hospital Associations 
and Outcomes,” New Orleans, LA 
05/16/14 Presenter, Report from the 2014 U13 AGS-NIA Conference - Delirium 
in Older Adults: Finding Order in the Disorder, Annual Meeting of the 
American Geriatrics Society, “Delirium and Dementia,” Orlando, FL 
05/16/15 Presenter, American Geriatrics Society 2015 Annual Meeting, 
Geriatrics Consultative Services Special Interest Group (SIG), 
“Geriatricians as Consultants for Cognitive Impairment,” Oxon Hill, MD 
03/29/16 Presenter, University of Illinois at Chicago, Department of Medicine, 
Grand Rounds, “Current and Future Treatments for Alzheimer’s 
disease,” Chicago, IL  
Presenter, University of Illinois at Chicago, Department of Medicine 
and Geriatric Medicine Fellowship Lecture, “Interrelationship of 
Delirium and Dementia,” Chicago, IL 
03/31/16 Presenter, University of Chicago, Section of Geriatrics and Palliative 
Medicine Grand Rounds, “Postoperative delirium,” Chicago, IL 
 
International 
08/06/10 Presenter, XV Symposium Internacional de Geriatria y Gerontologia, 
“Advances in the Dementias; Mild Cognitive Impairment,” 
Guadalajara, Mexico 
09/15/10 Presenter, International College of Geriatric 
Psychoneuropharmacology, Junior Investigator Award Presentation, 




07/13/13 Presenter, Alzheimer’s Association International Conference (AAIC), 
Anesthesiology Symposium: “Perioperative Management of 
Cognition,”Boston, MA 
07/12/14 Presenter, Alzheimer’s Association International Conference (AAIC), 
Perioperative Cognition Professional Interest Area (PIA), Pre-
conference Symposium, “Cognitive Recovery after Cardiac Surgery 
and the Role of Delirium,” Copenhagen, Denmark 
08/10-16/14 Presenter, The Sino-US Academic Forum, The Second Hospital of 
Dalian Medical University, Medical Co-morbidities in Dementia Care, 
“Interrelationship of Delirium and Dementia; Treatments for 
Alzheimer’s disease,” Dalian, China  
07/21/15 Presenter, Alzheimer’s Association International Conference (AAIC), 
Research Symposium, “Delirium and Its Sequelae,” Washington DC 
09/04/15 Presenter, European Delirium Association, CSF studies in delirium 
research: lessons learned and future directions, “Standardization of 
Biomarkers,” London, United Kingdom 
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J. O’Brien, Constantine G. Lyketsos, Frederick E. Sieber, and Simon C. Mears 
(July 2012) Correlation of Cerebrospinal Fluid (CSF) Amyloid-β42 and Tau 
Levels with Postoperative Delirium Severity in Patients Undergoing Hip Surgery, 
Alzheimer's Association International Conference on Alzheimer's Disease. July 
16, 2012. Vancouver, Canada  
16. Esther S. Oh,  Paul B. Rosenberg,  Hochang B. Lee, Allison E. Carlson,  Richard 
J. O’Brien, Constantine G. Lyketsos, Frederick E. Sieber, and Simon C. Mears 
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Levels with Postoperative Delirium Severity in Patients Undergoing Hip Surgery, 
14th Annual ACCM Research Day, December 10, 2012 Baltimore, MD. 
17. S. Shackford, PB. Rosenberg, ES Oh. The Effects of Cognitive Impairment on 
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discontinuation and patient outcome in a chronic geriatric medical/psychiatric 
unit: A retrospective chart review. J Am Geriatr.Soc. 2013:61.S65 
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clinic based hearing intervention for persons with dementia. American Auditory 
Society Scientific and Technology Meeting March 5-7, 2015. 
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Frank Lin. Hearing intervention to improve communication for persons with 
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2015. 
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A. Wolk, David F. Tang-Wai, Francisco A. Ponce, Wael F. Asaad, Marwan 
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Developing Topics, Alzheimer’s Association International Conference July 22, 
2015 
27. Wong D, Borroni E, Kuwabara H, George N, Rosenberg P, Lyketsos C, Resnick 
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Muri D, Carey T, Bedding A, Wandel C, Hansrod T, Honer M, Moghekar A, 
Boess F, Albert M, Shaya E, Oh E, Ostorwitzki S, Dannais R, Comley R. First In-
Human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, 
[11C]RO6931643, and [18F]RO6958948. Developing Topics, Alzheimer’s 
Association International Conference July 22, 2015 
28. Sara K. Mamo, Olivia Nirmalasari, Carrie Nieman, Matthew McNabney, Esther 
Oh, Frank Lin. Aural rehabilitation in geriatric clinic and group care settings. The 
7th Biennial National Center for Rehabilitative Auditory Research (NCRAR) 
Conference, September 16-18, 2015 
29. Fornix deep brain stimulation for Alzheimer’s disease: results of the Multi-center 
Advance Trial. Oral communication, Clinical Trials on Alzheimer’s Disease 
(CTAD 2015), November 5-7, 2015 
30. Aisha Harun, Robin Bigelow, Esther Oh, Yuri Agrawal. The association between 
vestibutlar function and visuospatial ability in individuals with dementia. 
Association of Research in Otolaryngology (ARO), February 20-24, 2016  
31. Aisha Harun, Robin Bigelow, Esther Oh, Yuri Agrawal. Vestibular function is 
impairment in individuals with dementia. Combined Otolaryngology Spring 
Meetings (COSM), May 18-22, 2016 (accepted) 
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Communication between caregivers and participants in Program of All-Inclusive 
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Visuospatial Function in Individuals with Dementia, American Academy of Head 
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34. Oh ES, Tucker SM, Rudow GL, Jankowsky JL, Borchelt DR, Troncoso JC. 
Passive immunization with monoclonal antibody Aβ 1-11 in transgenic mouse 
models of Alzheimer’s disease. American Association of Neuropathologists 2005 
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